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Title: Investigating the transcriptional regulation of BCL11A in Triple-
negative Breast Cancer 
Name: Nicola Tsang Hoi Yee 
Breast cancer is the most common type of cancer in women worldwide. It can be 
classified into several subtypes based on the histological expression of Estrogen, 
Progesterone and HER-2 receptors. The most aggressive subtype of breast cancer 
is called Triple-negative breast cancer (TNBC) and is clinically defined by the 
absence of the three receptors mentioned above. These TNBC patients have the 
poorest prognostic outcome among the subtypes and highest mortality rate due to 
the lack of targeted treatments.  
A recent study has shown the expression of the transcription regulator BCL11A, to 
be upregulated specifically in TNBC compared to the other subtypes of breast 
cancer. In addition, BCL11A has also been experimentally demonstrated to be an 
oncogene in these aggressive tumours, thus making it an interesting target for new 
drug developments. However, little is known about how BCL11A is regulated at the 
transcriptional level in breast cancer. To tackle this problem, this project 
implements a novel proteomic approach utilising the Clustered regularly 
interspaced short palindromic repeats – CRISPR associated 9 (CRISPR-Cas9) 
technology, to identify putative transcriptional regulators of BCL11A in TNBC.  
The first step of this project involves the identification of regulatory sites on 
BCL11A that display high transcriptional regulations. This was achieved using the 
CRISPR-Cas9 knock-out approach. We then employed the mutated catalytically 
inactive Cas9 (dCas9) to target these sites and to pull down proteins in close 
proximity. This novel approach led to the identification of DEK, SSRP1 and PSIP1 
as potential regulators of BCL11A’s expression. Experimentally, I found knocking-
down DEK, SSRP1 and PSIP1 resulted in a reduction in BCL11A’s expression in 
TNBC. These results highlight a novel approach for the identification of 
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transcription regulators of BCL11A’s in TNBC and potential targets for therapeutic 
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1.1 Introduction 
Breast cancer is the most common type of cancer in women residing in the United 
Kingdom (UK) [1]. It has been estimated that 1 in 7 women will have breast cancer 
some time in their life [2]. In order to understand this disease, researchers 
investigate breast cancer with the aim to understand the molecular underlying and 
to develop ways to tackle these causes. These have been made possible thanks to 
advancement in technology, which allows us to classify breast cancer patients 
clinically under the umbrella of subtypes characterised by specific gene and protein 
expressions. Broadly speaking, breast cancer can be classified into two subtypes: 
one expressing hormonal receptors and another without. These are in turn further 
classified into intrinsic subtypes through the study of gene expression profiles. 
The hormonal receptors negative subtype is called Triple-negative breast cancer 
(TNBC). It does not express receptors for the hormones Estrogen and Progesterone, 
nor the Human epidermal growth factor (HER)-2, thus making conventional 
treatments which target these receptors unsuitable for treating TNBC patients and 
posing a challenge to find new molecular targets for drug development. Studies of 
this subtype have led to the identification of B-cell lyphoma/ leukaemia 11A 
(BCL11A) as an oncogene and a potential drug target. However, its regulation in 
TNBC remained to be determined. Therefore, this project aims to investigate the 
regulation of BCL11A in TNBC using the Clustered regularly interspaced short 
palindromic repeats (CRISPR) – CRISPR associated protein 9 (CRISPR-Cas9) 
system and proteomic approach. Chapter 1 will give an overview of present 
knowledge in the field of breast cancer, BCL11A, and the research techniques used 
in this project.  
1.2 Breast cancer 
Breast cancer is globally the most common type of cancer in females, contributing 
to 15% of new cancer cases in 2008 [3]. Breast cancer is also the most common 
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type of cancer in women since 1997 [1]. In 2018 alone, two million new cases were 
diagnosed in the UK [4].  One contributing factor to an increase in the number of 
diagnosis in the UK relative to 1990s is that women between the ages of 50 and 70 
now receive screening every three years [5]. It has been estimated that one person 
is diagnosed every ten minutes per day [6]. As a result of this good national 
screening programme, the rate of mortality has been reduced and the survival rate 
has doubled in the past forty years. Despite this, the rise of new cases remained 
steady. A cancer research organisation has predicted that one in seven women 
would develop breast cancer during their lifetime [2]. A wide range of risk factors 
have been identified, including aging, excessive alcohol consumptions, obesity, 
increasing breast density and drugs such as hormone replacement. In addition, 
being of certain ethnicities, such as African-descendent American, could also 
increase susceptibility to breast cancer, as demonstrated in the Carolina Breast 
cancer study [7]. Cancer starts by inheriting or acquiring genetic aberrations 
accumulated through life. These mutations can lead to changes in gene expressions 
and disruptions of molecular components or cellular pathways.  
1.2.1 Anatomy of the breast and the mammary gland 
The breast consists of various cell types including the adipose cells and the 
epithelial duct lobular units. These duct lobular units ultimately function by 
producing milk at the lobules and secreting it through ducts that connect the lobules 
to the nipples for new-born infants. These duct lobular units are also called the 
mammary gland.  
The mammary gland is unique in that most of its development occurs in adulthood 
and it only reaches maturity during pregnancy under the influence of hormones [8] 
[9] [10]. Its development is arrested after birth and restarts again when a female 
reaches puberty. Figure 1.1 describes the changes in the mammary gland at puberty, 
during and after pregnancy. During puberty, Estrogen and Progesterone initiate 
ductal growth into the fat pad and these growing ducts have cap-like structures at 
the tips called the Terminal end buds (TEB) [11] [12] [13]. These TEB are areas 
with high proliferation rates that can fill the fat pad with primary and secondary 
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branches [14]. In addition, side branching also occurs in the matured virgin. The 
mammary gland development then reaches a halt and continues during pregnancy, 
when a change in hormonal signalling initiates tertiary branching and the TEB 
develops into milk-producing alveoli for nourishing infants [15]. The mammary 
gland is a bilayer epithelium consisting of two cell types: luminal and basal cells. 
The luminal cells face the inner side of the ducts and alveolar while basal cells, 
which is also called myoepithelial cells, line and face the outer side [16]. These 
myoepithelial cells are responsible for ejecting milk from the alveolar into the ducts 
during lactation. Upon the loss of demand for milk from the new-born, the 
mammary gland undergoes a series of cell death events and tissue remodelling 
called involution [17] [18] [19] . This returns the gland to the pre-pregnant stage 
where primary and secondary branching are still missing. 
The different cell types in the mammary gland are thought to be the reason for the 
heterogeneity in breast cancer, as the various subtypes of breast cancer could 
originate from different cell types in the mammary gland [20]. I will now give an 
overview of the traditional and current methods for classifying breast cancer 
subtypes. 
1.2.2 Classifying breast cancer subtypes 
Traditionally, pathologists use histological analysis to diagnose breast cancer 
subtypes with established markers: Estrogen receptor (ER), Progesterone receptor 
(PR), and Her-2 receptor. Presence of the first two traditional hormonal receptors 
is determined by Immunohistochemistry (IHC). As for the third, amplification of 
the Her-2 coding gene, Erb-B2 receptor Tyrosine kinase 2 (ERBB2), is determined 
by Fluorescence in situ hybridisation (FISH). The identification of these markers in 
breast cancer samples has also led to the classification of patients into four main 
subtypes: ER-positive, PR-positive, Her-2 overexpressed, and Triple-negative 
breast cancer, the last of which does not express any receptors nor has Her-2 
amplified. Apart from the identification of subtypes, histological staining also 
revealed the grading of aggressiveness based on morphological features of 
differentiation and proliferation [21].  [22] 
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1.2.2.1 Clinical decisions 
Both subtyping and grading systems from histological staining are thought to 
provide prognostic information and help to predict clinical outcomes. Thus, medical 
practitioners have been utilising these results when making decisions on the best 
treatment available for breast cancer patients. Traditional anti-hormonal treatments 
were often administered to treat ER- or PR-positives. This drug class works by 
inhibiting hormones, ER or PR, from binding to their receptors and thus stopping 
cell growth. Tamoxifen was the first anti-hormonal drug developed among this drug 
class and is prescribed for patients with ER-positives [23]. Apart from anti-
hormonal treatments, Aromatase inhibitors were also prescribed for ER-positives. 
These work by blocking the enzyme, Aromatase, from converting Androgen into 
Estrogen [24]. This drug class is prescribed preferentially to post-menopausal 
patients due to changes in the source of Estrogen; the female sex hormone Estrodiol 
is the primary form of endogenous Estrogen in women before menopause, while 
Androgen becomes the predominant source in post-menopausal patients [25]. In 
contrast, the main treatment for Her-2 positive patients is monoclonal antibodies 
which bind to the Her-2 receptor and prevent activation of the receptor and its 
downstream kinase cascades.  
None of the drug classes described above is prescribed for TNBC patients due to 
the lack of hormonal and Her-2 targets. Therefore, chemotherapy is the only option 
available for these patients and the characterisation with IHC approaches are not 
accurate enough to meet the subtype’s need [26] [27]. Not helping the case is the 
common phenomenon that regardless of subtype, outcomes of treatments often 
differ from what would be expected based on observed clinical behaviours. This 
urges the development of new, well-defined makers for classification and 
therapeutic approaches.  
1.2.2.2 Subtyping with molecular markers 
Advancements in diagnostic techniques have led to further subtyping of breast 
cancer, identification of new drug targets, and better prognostic predictions. In 
Page | 8 
 
2000, Perou et al. [28] proposed to classify subgroups by microarray. These gene 
expression profiles have deepened the understanding of breast cancer 
heterogeneity. Moreover, it has revolutionised breast cancer subtyping by 
introducing five ‘intrinsic subtypes’: Luminal A, Luminal B, Her-2-enriched, 
Basal-like and normal. An additional subtype, Claudin-low, also became a member 
in 2007 [29]. Despite their names, overlaps were found between subtypes identified 
from microarrays and IHC. These are presented in Table 1.1.  
1.2.2.2.1 Heterogeneity 
Breast cancer heterogeneity is not only observed in the expression of receptors but 
also in gene expression profiles. The diversity of gene expressions can be 
interpreted as spatial or temporal control to adapt their microenvironment, and 
mutation of gene expressions could lead to metastasis. Despite such heterogeneity, 
the histological detection of ER remains the main marker for determining clinical 
treatments for patients.  
In order to develop more targeted therapeutic strategies, there is a need for a 
classification of breast cancer that captures heterogeneity better. For that purpose, 
studies have integrated ‘intrinsic subtypes’, genomic aberrations, and clinical 
outcomes. The Molecular Taxonomy of Breast Cancer International Consortium 
(METABRIC) study combines the copy numbers and gene expression profiles from 
2000 patients [31]. METABRIC also contributed to The Cancer Genome Atlas 
(TCGA) dataset which shows heterogeneity at the genetic and molecular levels 
[32]. Information from the TCGA database is often expressed as the Prosigna breast 
cancer prognostic signature assay (PAM50) which classifies the intrinsic subtypes 
by analysing the co-expression of 50 mRNAs [27].  
1.2.2.3 Basal-like and Triple-negative subtype 
Basal-like breast cancer (BLBC) resembles the morphology of the basal cells of the 
mammary gland. This subtype is often classified using microarray and IHC 
techniques with high sensitivity against basal elements [33], such as cytokeratin 5, 
6, 14 [34], 17 [28], P-cadherin [35] or Epidermal growth factor receptor (EGFR)  





Luminal A ER- /PR- positives, low proliferation rate, best prognosis 
Luminal B ER- &/ PR- positives, higher proliferation rate, less 
responsive to hormonal treatments, worse prognosis than 
Luminal A 
Her2-enriched Amplified ERBB2 or genes from the same chromosome, 
high grade 
Basal-like Markers of the breast’s basal cells, aggressive, poor 
prognosis 
Claudin-low Similar gene expressions as mammary stem cells 
Normal Markers resemble normal breast tissues 
Table 1.1: Intrinsic subtyping by Perou et al and the characteristics of each 
subtype.  
Table 1.1 presents the overlaps of subtypes identified using microarrays, IHC 
methods, and intrinsic subtypes. In addition, it also shows certain characteristics of 
subtypes, such as differences in the proliferation rate, prognosis, and resemblance 
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[33] [36]. BLBC contributes to 20% of diagnosed breast tumour cases [3] and 
shares a lot of features with TNBC. 80% of TNBC cases were identified as BLBC, 
since both lack hormonal receptors for ER and PR and the amplification of Her-2 
from histology analysis. They are also generally high graded tumours with elevated 
proliferation rates from dysregulating pathways or components of the cell cycle 
[37]. For example, gene expression analysis detected high levels of Cyclin E1 
which promotes Gap 1/ Synthesis (G1/S) phase progression in the cell cycle [38] 
[39]; loss of Phosphatase and tensin homolog (PTEN) which regulate 
Phosphoinositide 3- kinase (PI3K) activities [27]; and reduced expression in tumour 
suppressor retinoblastoma protein 1 (Rb1), resulting in the upregulation of cyclin-
dependent kinase I, p16 [37] [40] [41]. Mutations in tumour suppressor Tumour 
protein p53 (p53) are also commonly found in BLBC [41].  
Apart from the molecular similarities between BLBC and TNBC, the two share 
clinical features including young age (<50 years old), higher susceptibilities in 
African-Americans, poor prognosis with recurrences in three years after initial 
treatment [3], and a higher mortality rate than the rest within a five year period [42]. 
Their aggressiveness can also be seen from overexpressed genes from the Ras-Raf-
MEK-ERK (MEK/ ERK) pathway, which promotes cellular invasion, and high 
levels of associated genes in the epithelial-mesenchymal transition (EMT) 
mechanism from Sarrió’s study [43]. EMT starts by changing the expression of cell-
surface markers and cell-cell adhesion molecules, followed by overexpression of 
proteins responsible for remodelling the extracellular matrix [43]. These 
simultaneous events allow tumour cells to detach from their original sites and 
colonise elsewhere in the body. An eight year clinical study [44] found a higher 
proportion of TNBC patients to have experienced metastasis, while a median of one 
year survival in metastased TNBC patients was reported by the Abramson group 
[45]. Furthermore, TNBC was found to have metastatic potentials to specific 
tissues, such as the central nervous system [44], liver, and the brain [33].  
Page | 11 
 
1.2.2.3.1 Developing treatments for TNBC patients 
Despite our knowledge of this subtype, treatments are still mostly limited to 
chemotherapy and the high mortality rate remains unsolved. One way to overcome 
these is to repurpose existing drugs to treat TNBC patients. An example would be 
Cetuximab. It is an inhibitor for the epidermal growth factor receptor and has been 
administered for treating metastased colorectal cancer [46] [47] and several types 
of cancer [48] [49] [50] [51]. The rationale behind using Cetuximab to treat TNBC 
patients is the expression of EGFR in 60% of this subtype [52]  and the availability 
of this drug. However, treatment with Cetuximab in these patients showed low 
response rates in a clinical trial [53] [54]. 
The failure to repurpose an existing drug in this example means there is a pressing 
need for researchers to identify molecular makers for new drug developments. One 
example of how research can guide new drug development is the frequent 
identification of BRCA1 mutations in TNBC patients. Hypermethylation of the 
BRCA1 promoter is found to downregulate ER [55] and upregulate basal markers 
[56], thus leading to the proposal of its contribution to TNBC development. This 
suggests that poly Adenosine diphosphate (ADP)-ribose polymerase (PARP) 
inhibitors can possibly be used to treat these patients [42] [57].  
A novel oncogene, BCL11A was recently identified by our group as a potential 
molecular marker that can address the challenge of improving prognosis for the 
TNBC subtype.  
1.3 BCL11A 
BCL11A protein is the human homologue of EVI9 [58], originally found from  
studying myeloid leukaemia tumours in mouse models. This gene is highly  
conserved on chromosome 2 in humans, with 94% homology to mouse’s BCL11A 
at the nucleotide level, 95% at the amino acid level [59], and 98% at the protein 
level [60]. Another member of the BCL11 family, B-cell Leukaemia 11B (BCL11B) 
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protein is 67% similar to BCL11A in terms of nucleotides and 61% at the protein 
level [60]. Moreover, they both bind to the consensus G-C rich motif at the 
promoter region of their target genes or in their binding partners presented in Table 
1.2 [59] [61] [62].  
BCL11A contains five exons with long introns encoding for Cys2His2 (C2H2)-like 
fold group type zinc-fingers protein. Alternative splicing of the exons gives rise to 
four isoforms: XS, S, L, and XL which differ in protein lengths and domains [59]. 
Figure 1.2 demonstrates the features and domains in these isoforms. All four of 
them encode for the zinc-finger at the N-terminus, along with the 12 conserved 
amino acids upstream. The main difference is the number of zinc-fingers at the C-
terminus and thus the resulting protein length. Additionally, only L and XL 
isoforms have a proline-rich section and acidic domain from exon four [60]. Despite 
the similarity in size, Pulford et al. [63] successfully distinguished between the two 
isoforms and found the expression of XL to be the most abundant in cells.  
1.3.1 Expressions and roles in biological systems 
BCL11A is expressed diversely in tissues including the brain, kidney, 
haematopoietic stem cells (HSC) in the bone marrow, and other lymphoid tissues 
 [59]. Isoforms also have preferences in spatial expressions; for example, the short 
form is expressed in erythrocytes progenitors [64] or foetal liver [58] while the long 
form is predominantly expressed in the bone marrow [59]. 
1.3.1.1 Roles in the immune system 
1.3.1.1.1 Roles in silencing γ-globin chain and globin chain switching during 
development 
BCL11A has a major role in regulating haemoglobin (Hb) F level [64]. Switching 
from γ- to β globin in Hb adult (HbA) is achieved by interacting BCL11A and its 
binding partners with one another and then binding them at various regions of β-
globin gene cluster. These are shown in Table 1.2 and Figure 1.3. Dysregulation of  
 
















Figure 1.2: Structure of the BCL11A gene and the four isoforms.  
The BCL11A gene has five exons with long introns in-between. It starts with a long 
CpG island with a highly conserved region, followed by the 5’untranslated region 
(UTR) prior to exon 1. An additional highly conserved region is present in the last 
zinc finger encoded on exon 4. Exon 2 translates to a zinc finger present in all 
isoforms and varying numbers of zinc fingers are translated from exon 4 in isoforms 
S, L, and XL. In addition to these isoforms, XS is created through alternative 
splicing. The conserved region among the CpG island, the 5’ UTR downstream, and 
exons 1 and 2 are present in all isoforms. Exon 3 is present in S, L, and XL isoforms, 
whereas different fragments of exon 4 are found in isoforms S and L. XL is the only 
one with the full exon 4 which translates into six C2H2 zinc fingers. Moreover, a 
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Hb foetal (HbF) levels could result in sickle cell anaemia or β-thalassemia [62] [64] 
[65]. 
1.3.1.1.2 B-cells and T-cells developments 
The second role of BCL11A in blood cells is to regulate the development of B- and 
T- lymphocytes during lymphopoiesis [66]. B-cell differentiation and cell survival 
are regulated by haematopoietic regulator BCL6 [64] and anti-apoptotic BCL2 
protein, respectively. At the same time, BCL11A regulates T-cell maturation by 
utilising the Mdm2-p53 pathway [68]. Mutations could lead to B-cell lymphoma 
leukaemia by transrepressing genes through histone deactylase, SIRT1, and to T-
cell lymphoma by triggering over-production through Notch 1 signalling [69].  
1.3.1.2 Roles in the neural system 
BCL11A has also been identified to have a number of roles in the neural system, 
such as axon branching and dendrite outgrowth. These are achieved through the 
guidance by regulating Class 3 semaphorins to interact with the plexin 
transmembrane receptors [71]. Outside of participating in different functions by 
regulating genes and proteins in the neural system, BCL11A when mutated is also 
found to be the cause of various neuronal diseases. For example, microdeletion of 
BCL11A results in autism spectrum disorder (ASD) [71] and single nucleotide 
polymorphism (SNP) in Schizophrenia [72].  
1.3.1.3 Roles in Lung cancer 
Apart from the identification of BCL11A in TNBC, studies by our group have also 
found BCL11A to be an oncogene in Lung squamous cell carcinoma (LUSC) [73]. 
LUSC is one of the non-small cell lung cancers (NSCLC) with limited targeted 
therapies and patients are often treated with Platinum-based drugs as the first line 
of defence [73]. Our results have shown BCL11A to regulate transcription factor 
SOX2, and the two regulate SETD8 together. Inhibiting SETD8 also resulted in the 
inhibition of tumour growth which suggests that BCL11A-SOX2 interaction has 
potential as a new drug target.  
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Binding partners Functions 
SOX6 Directly interacts with BCL11A to regulate globin 
switching [65] 
Matrin-3 Assists BCL11A binding to nuclear matrix and interacts 
with β-globin gene [63] 
GATA 1 – FOG 1 Bridging between BCL11A and distant site of β-globin 
gene to regulate globin switching [63] [70] 
NuRD complex Anti-apoptotic protein of B- and T-cells survival [63] 
BCL2 Hematopoietic regulators for germinal centre formation 
[68] 
BCL6 Member of Histone Deactylase family regulating 
transcription repression [62] [67] [68] 
SWI/SNF complex Chromatin remodelling for transcription machineries to 
access and transcribe genes [65] 
Table 1.2: Examples of BCL11A binding partners and their roles in relation to 
the functions of BCL11A.  































Figure 1.3: Structure of the β- globin gene clusters.  
The β- globin gene clusters are found on chromosome 11, with Locus control region 
(LCR) at the 5’end and Haematopoietic lineage cell-specific protein 1 (HS1) at the 
3’end. It also has multiple globin genes expressed in a developmentally sequential 
order - Embryonic (ε), Fetal (G gamma (γ) and Aγ), Delta (δ) and Beta (β). BCL11A 
works in concert with multiple proteins to form a complex in silencing fetal γ gene 
and transcribing adult β gene during development. These are part of the subunits 
which form tetrameric Hb. LCR is a common site bound by BCL11A and other 
proteins such as SOX6 and GATA1. Haematopoietic regulators such as GATA1 and 
FOG1 bind to the genomic region between γ and δ, a site that the Mi2/NuRD 
repressor complex also binds to in addition to the gap between δ and β. All these 
proteins work as one to silence γ-globin and initiate the transcription of β-globin by 
recruiting RNA polymerase (RNAP) II complex. (Modified from [64] [65]) 
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1.3.1.4 Roles in Triple-negative breast cancer 
I have described the regulation of BCL11A in different biological systems in the 
above sections, but its regulation in the context of TNBC is not yet known. Attempts 
have been made by our group to understand this. It has been extensively 
demonstrated that BCL11A regulates the development of haematopoietic cells, and 
mutations can lead to malignancies. Considering the regulations in B-cell 
lymphoma leukaemia, one would speculate BCL11A to transrepress genes in a 
similar manner through histone deacetylase SIRT1. Nevertheless, the level of 
SIRT1 remains unchanged in mouse models where carcinogen 7,12-
Dimenthylbenz[a]anthracene (DMBA) was used to induce tumourigenesis [74]. 
This raises the possibility that BCL11A’s regulation is context dependent and thus 
it is important to investigate the roles and regulations of BCL11A in the TNBC 
subtype.  
Screening from a clinical dataset has found BCL11A to be highly expressed and 
with genome instability, as demonstrated by an increase in copy number and gene 
expression in TNBC. BCL11A was also found to have hypomethylated specifically 
in these tumour cells [74]. Hypomethylation can be a de novo or heritable 
epigenetic change and is often found in satellite DNA or oncogenes [75]. 
Demethylation is a process which removes methyl groups from cytosine and 
adenine bases, allowing transcription machineries to access or recruit histone 
associated proteins. 
Experimental works have been conducted to investigate the role of BCL11A in the 
context of TNBC. Increase in mammospheres and tumour sizes were observed by 
overexpressing BCL11A in vitro and in vivo, respectively; knocking-down its 
expression has also led to a reduction in tumour size. These suggest its importance 
in tumourigenesis. Reduction in tumour sizes through BCL11A deletion suggests its 
involvement in tumour maintenance. All these evidence support the role of BCL11A 
as an oncogene of TNBC. Screening through clinical databases further 
demonstrates the specificity of BCL11A expression found in this particular subtype. 
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However, the regulation of BCL11A expression and downstream pathways in 
Triple-negatives awaits to be discovered.  
1.4 Transcriptional regulation 
Before looking deeper into the regulation of BCL11A, I will first give a general 
overview of transcription and examples of regulating this process. Transcription is 
important for regulating gene expression and transcribing deoxyribonucleic acid 
(DNA) into messenger ribonuclease acid (mRNA) by ribonuclease acid (RNA) 
polymerase for transferring genetic information. These mRNA will then be 
translated into proteins. Figure 1.4 presents the major steps in transcription: 
initiation, elongation, and termination. Transcription starts at the initiation stage by 
recruiting a pre-initiating complex, composed of many transcription factors with 
general or specific roles, to a transcription start site and initiates by adding a 
complementary nucleotide. The RNA polymerase then moves along the DNA 
strand while extending the mRNA, in a process called elongation. Finally, 
termination occurs upon the arrival of the RNA polymerase at a stop codon that 
signals it to terminate transcription, release the mRNA transcript, and dissociate 
from the DNA strand.  
There are a number of ways to regulate transcription. For example, epigenetic 
control modifies DNA or histone proteins for the accessibility of DNA sites for 
transcription [76]. This can result in gene activation or repression. An alternative 
mechanism involves DNA forming a loop between the promoter regions and 
enhancers or repressors, followed by the recruitment of transcription factors [77].  
1.4.1 Transcription factors 
Transcription factors are proteins which bind at specific DNA sequences to regulate 
gene expression. This tight regulation is important for many cellular processes such 
as cell growth, differentiation, and survival. Transcription factors can act alone or 
in concert with other proteins to activate or repress genes by modulating the  




Figure 1.4: An overview of the processes in transcription. 
Initiation starts when RNA polymerase binds close to the promoter region on the 
DNA and recruits a pre-initiating complex. RNAP then moves along the DNA 
strand while transcribing and extending the new mRNA transcript. This process is 
called elongation. Termination occurs when RNAP reaches the sequence that code 
for a stop codon. The RNAP then releases the mRNA transcript and dissociates 
from the DNA strand. (Obtained from [78]) 
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accessibility of DNA regions needed for transcription, or by recruiting co-activators 
and co-repressors.   
It is known that tumour cells have upregulated levels of transcription and targeting 
cell proliferation has been a common thought for treating cancer patients. Proteins 
such as transcription factor are one type of possible targets. Proteomics is the name 
given to the study of protein, And in this project, I will be using the proteomics 
approach to study transcriptional regulations of BCL11A.  
1.5 Proteomics studies 
Advancement in technology has given rise to new ways for classifying breast cancer 
patients, one of which is gene expression profiling. This allows further 
characterisations and tailored treatments based on a patient’s genetic component.  
However, the use of gene expression has a disadvantage in that transcripts are not 
necessarily translated into proteins. Moreover, it is estimated that the human 
genome contains 20,000 protein-coding genes which can give rise to 500,000 
protein isoforms through alternative splicing and post-translational modifications 
[79]. As a result, genetic information alone may not be detailed enough for tailoring 
specific treatments to individual patients. Hence, the study of proteomics can add 
another level of accuracy and sophistication.  
 
Another reason for the study of proteomics is that it allows us to relate between 
genome and protein functions. In particular, genome is related to both the 
expression and abundance of proteins. Therefore, understanding the relationship 
between genome and protein functions can aid us in disease prediction. In close 
connection to this, the study of proteins may also lead to the development of new 
biomarkers for early detections and improved prognosis. 
Yet another reason for studying proteomics comes from the fact that a protein can 
potentially participate in a large number of roles; see for instance the earlier 
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example of BCL11A in different biological systems. By understanding these 
different roles of proteins, we can predict their involvement in more complex 
networks in cancer, for instance in signalling pathways, tumour progression, and 
response to therapies.  
In summary, proteomics can help to predict diseases, develop new therapeutic 
ways, and overcome clinical challenges when treating breast cancer patients.  
1.5.1 Traditional methods to study proteomics and Rapid 
Immunoprecipitation of endogenous proteins with mass spectrometry (RIME) 
For decades, protein identification has been achieved through two-dimensional gel 
electrophoresis (2D-PAGE) [80]. This technique first separates proteins on a gel 
based on their isoelectric point and then by their molecular weight, thus producing 
a specific ‘dot’ on the gel. Each of these ‘dots’ can then be passed on to mass 
spectrometry, a widely used technique in proteomic studies, for protein 
identification.  
The identification of protein leads to the study of protein-protein interactions using 
various affinity chromatography techniques. Potential candidates are then validated 
using Fluorescence resonance energy transfer (FRET) and Proximity ligation assay 
(PLA) [81]; both present results as signals when protein partners are in close 
proximity. Alternatively, they can be validated using co-immunoprecipitatioin (Co-
IP) which pulls-down partners using one as bait and vice versa. However, Co-IP 
has several drawbacks. Multiple washings between steps could result in the loss of 
proteins with transient interactions. Previous knowledge of the specific protein-
protein interactions is required before Co-IP can be performed. Poor quality 
antibodies may also produce false negatives [82]. Finally, endogenous proteins are 
found at a lower concentration in their native state than when used experimentally, 
and this difference in expression levels may also explain the failure in validating 
some of the protein partners experimentally.  
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To overcome these problems, RIME is employed. RIME is a technique developed 
recently to study and identifies unknown proteins. It couples chromatin 
immunoprecipitation (ChIP) with mass spectrometry to identify DNA-protein or 
protein-protein interactions in living cells [78]. ChIP is a commonly used technique 
to study DNA-protein interactions in cells, and its adaptation into the RIME 
protocol changes the application of ChIP from studying interactions to pulling-
down proteins or partners on a specific piece of DNA for later identification using 
mass spectrometry. Figure 1.5 outlines the steps in RIME.  
Similar to ChIP, cells are first fixed using formaldehyde to fixate and preserve 
transient or long-lasting, weak or strong interactions [83]. Formaldehyde is 
commonly used in ChIP and cell fixation protocols due to its small size, non-
specificity to targets, reversibility, and the ability to cross membranes [83]. To 
study transcription factors, the nuclear fractions are then extracted from the cell 
pellets and broken up into small DNA fragments. They are then 
immunoprecipitated to purify the protein of interest with its binding partners and 
further processed with mass spectrometry to identify the unknown proteins. The 
advantage of using RIME here is that no prior knowledge of potential protein 
partners is needed, whereas traditional methods such as affinity chromatography 
may require some knowledge such as the size or charge of the unknown protein 
[84]. The RIME technique is used in this project to study transcription factors which 
bind at specific BCL11A genomic regions and regulate its expression. 
1.5.2 Applications of RIME 
Since its development, RIME has been used in a number of studies. For example, 
protein partners were identified for maintaining stemness in the human trophoblast 
stem cells for controlling placenta development [85]; for tumourigenic functions in 
prostate cancer [86]; and as part of a complex to function as a tumour suppressor 
[87].  
A good example of using RIME to identify transcription factors is the identification 
of Growth regulating Estrogen receptor binding 1 (GREB1) in ER-positive breast  
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Figure 1.5: The major steps in RIME.  
Cell cultures are fixed with formaldehyde. Diagrams onwards represent actions at 
the genomic level. Primers from the CRISPR-Cas9 system are bound to the target 
sequences through complementary base pairing with the help of catalytically 
inactive Cas9. Nuclease activities of Cas9 are silenced, allowing the RNA-hybrid 
Cas9 complex to bind to target DNA without inducing double-strand breaks. 
Sonication breaks up the loci into small DNA fragments and V5-bound antibodies 
are used in immunoprecipitation to pull down multi-tagged dCas9 along with any 
proteins bound in close proximity during the fixation stage. Samples are then 
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cell lines [88]. It has also been demonstrated that through coupling RIME with 
Stable isotope labelling by amino acids (SILAC) in cell cultures, investigators could 
identify differences in protein expression profiles under the effect of a drug [88]. 
Another example is the identification of Chromodomain helicase DNA binding 
protein 8 (CHD8) interacting with BCL11A in TNBC by our group.  
1.6 Genetic engineering and genome editing  
In addition to using RIME to identify putative transcription factors which may 
regulate BCL11A in TNBC, I also employ the CRISPR-Cas9 system for targeting 
specific regions of BCL11A.  
1.6.1 The CRISPR-Cas9 system 
1.6.1.1 Mechanism of the system 
CRISPR was originally used as a Type II adaptive immunity against foreign genetic 
material in bacteria or archea [89] [90]. This locus contributes to 45% of the 
bacterial genome [91].  
Foreign DNA such as viral DNA or plasmids contains short sequences of 20 
nucleotides called spacers. Upon first encounter, these spacers are cleaved and 
incorporated into the host’s DNA between the repeat sequences forming CRISPR. 
Bacteria and archea avoid secondary infections through a RNA-guided DNA 
recognition mechanism called Cas system, as illustrated in Figure 1.6. The Cas 
system starts with transcribing the CRISPR locus to pre-crRNA which is then 
processed into crRNA containing partial repeats and particular spacer sequences. 
This maturation process requires additional RNAs and proteins. Trans-encoded 
small RNA (TracrRNA) recognises the repeat in the pre-crNRA sequence and 
forms a hybrid with it. Excess sequences are cleaved off by host’s RNase III and 
forms a RNA-protein complex with endonuclease Cas9 [89]. CRISPR-Cas9 system 
identifies target DNA through complementary base pairings between the ‘seed 
sequence’ at the 5’ end of crRNA and target sequences [92]. Target recognition is 
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further secured by the presence of protospacer-adjacent motif (PAM) immediately 
downstream of the spacer [93]. This PAM site is important for multiple reasons. It 
is crucial for Cas9 binding as each ortholog has its own specific sequences. For 
example, Streptococcus pyogenes Cas9 has sequence NGG at its PAM site [94]. It 
is also important for distinguishing between self and foreign target sequences. 
Subsequent to DNA binding, Cas9 plays an important role in inducing double-
strand breaks with its HNH and RuvC nuclease domains [95]. These breaks are 
repaired by two DNA damage mechanisms described in Figure 1.7: the error prone 
Non-homologous end joining (NHEJ) that has a higher chance of introducing indel 
and frameshift mutations, and an alternative mechanism through precise homology 
directed repair (HDR) but which requires a template [96].  
1.6.1.2 Comparison between traditional genome editing techniques and 
CRISPR-Cas9 
Traditional genome editing approaches such as Zinc finger nucleases (ZFNs) and 
transcription-activator-like effector nucleases (TALENs) both rely on protein-DNA 
recognitions and require the design of a new nuclease for every target [99] [100]. 
These systems works by fusing the DNA-binding domains with endonucleases 
which induce double-strand breaks for genome engineering. In comparison to these 
techniques, the CRISPR-Cas9 system offers more simplicity in its design and 
application for genome engineering. Instead of having to design a new nuclease per 
target, users design a single guide RNA (sgRNA) for their specific targets. sgRNA 
is a fusion of crRNA and tracrRNA in the natural system and this alone is enough 
to guide the RNA-recognition system to the target DNA sites [101].  
1.6.1.3 Designing components for the CRISPR-Cas9 system 
The first part of refining this CRISPR-Cas9 technique is to custom design a gRNA 
which is complementary to the site of interest. This gRNA sequence is equivalent 
to the crRNA in the natural system for guiding the system to specific targets. Thus, 
it is important to optimise the design of gRNA for effective targeting while 
minimising off-target effects. A critical requirement includes having a PAM 
sequence immediately following the gRNA at the 3’ end for Cas9 recognition [92] 




Figure 1.6: The CRISPR-Cas9 system.  
The CRISPR locus consists of tracrRNA, Cas9 and spacers separated by repeats. 
Each spacers are unique and acquired from each invasion by foreign genetic 
materials in bacteria and archea genome. Upon second invasion, the corresponding 
spacer would be transcribed with parts of the repeat sequences to form pre-crRNA. 
This immature transcript is recognised by tracrRNA and endonuclease Cas9. 
Additional protein from the host RNase III is also required to cleave off excess 
repeat sequences to form mature RNA hydrid-Cas9 complex. crRNA is 
complementary to the target sequence and this brings the complex to the target. This 
system is also called RNA-guided DNA recognition. The PAM site immediately 
following the target is also critical for Cas9 recognition and binding. Cas9 is an 
endonuclease with two catalytic domains: HNH and RuvC domains which induce 
double-strand breaks and stopped the invasion. [97] [98] 
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 [93]. This PAM sequence is specific to the species of Cas9 used and could 
potentially affects the positions and activities of the gRNAs. The specificity of 
gRNA and the number of similar sites in the genome also contribute to potential 
off-targeting. The best site that matches these requirements can be predicted using 
publicly available web-based tools that allow gRNA to be designed based on the 
genomic regions of interest and built-in computational algorithms that predict their 
activities [102].  
1.6.1.4 Applications of the CRISPR-Cas9 system 
Cas9 is an effective nuclease which can be used to delete or correct DNA 
mismatches. The CRISPR-Cas9 system can also be employed in genetic 
engineering for introducing gene knock-out or knock-in [103], generating 
transgenic animal models [104], modulating transcriptional regulations [105], 
epigenetic modifications [106] or, in the case of this project, be used as a tag in a 
novel way.  
DNA double strand breaks induced by Cas9 can be repaired through the error prone 
NHEJ repair pathway. This is employed in gene knock-out experiments. Repair 
through this pathway introduces indel mutations which result in frameshift 
mutations [107] and premature stop of target gene’s transcription. On the other hand, 
DNA repair through the HDR pathway is utilised in gene knock-in experiments by 
providing template for the homologous recombination [108] and introducing the 
desired gene into cells or animal models. This HDR pathway was used in our group 
to generate BCL11A transcriptional reporter lines for studying genes which may 
regulate BCL11A in TNBC. Our results have identified E2F transcription factor 4 
(E2f4) and SET domain-containing protein 4 (Setd4) as potential novel regulators 
of BCL11A.  
In addition to the use of the DNA repair pathways, multiple forms of Cas9 can also 
be employed for various objectives for genetic engineering. An example would be 
to include single mutations in one of the Cas9’s nuclease domain and turn it into a 
‘nickase’. DNA binding could also be uncoupled with the nuclease activity, by 
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mutating H480A and D10A in HNH and RuvC doamins respectively in 
catalytically inactivate Cas9 (dCas9) [109]. Its mechanism is demonstrated in 
Figure 1.8. 
dCas9 can also be employed to regulate transcriptional activities by fusing with an 
effector, such as an activator or repressor, and guide it to sites close to the promoter 
to control transcription or affect epigenetic control [110]. However, one 
disadvantage of this system is Cas9 itself may affects gene expression by blocking 
the genetic regions and accessibilities of DNA for transcriptional machineries; this 
is referred to as CRISPR interference (CRISPRi).  
1.7 RNA interference technology 
RNA interference (RNAi) technology has been frequently used for gene silencing. 
It was originally discovered in C. elegans by Fire and Montagomery [111].  
Injection of double stranded RNA (dsRNA) has led to the degradation of mRNA 
which has the same sequence as these dsRNA [111]. RNAi is now a technique 
employed to inhibit gene expression or translation using exogeneous RNA 
molecules. One of these is the small interfering RNA (siRNA) that binds to the 
target mRNA transcript in a sequence-specific manner, thus creating dsRNA which 
leads to the degradation of mRNA and downregulation at the protein level [112].  
 
However, one disadvantage for siRNA is the short term expression and degradation 
by cellular machineries [113]. These can be overcome by the use of short hairpin 
RNA (shRNA) which combines siRNA with a loop structure called the T-loop and 
allows constitutive expression in the cell [113]. Figure 1.9 presents the mechanism 
of siRNA and shRNA. shRNA are first delivered into the cells  through transfection 
[114] or viral transduction [115]. They are transcribed in the nucleus by RNA 
polymerase III called Drosha, transported into the nucleus and then modified by 
RNase III Dicer to remove the T-loop and create siRNA with 20-25 nucleotides and 
a 3’ overhang. This siRNA is then loaded onto a RNA-induced silencing complex 
(RISC) with Argonaute family of proteins. Next, the double stranded siRNA in the  
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RISC unwinds and dissociates, leaving the sense strand as a guide for target 
recognition through complementary base pairing. Upon target identification, the 
RISC complex cleaves the target RNA’s phosphate backbone. The siRNA-target 
mRNA double stranded RNA duplex is then dissociated from the RISC complex 
and degraded by cellular machineries [116].  
 
This RNAi technology is used in this project post-identification of protein 
regulators of BCL11A for validation and functional investigations. 
1.8 Aims and outlines of this project 
The main aim of this project is to investigate the regulation of BCL11A’s expression 
in TNBC. To achieve this, I will use the CRIPSR-Cas9 system in combination with 
proteomics. The CRISPR-Cas9 system was used to target specific sequences from 
the BCL11A genome and RIME ultimately to identify proteins regulating BCL11A’s 
regulation in the TNBC subtype. 
Chapter 3 describes the experimental design of incorporating the CRISPR-Cas9 
system into our studies. In this project, I will use the catalytically dead form of Cas9 
to study the transcription regulation of BCL11A, focusing on regions which display 
active transcriptions. Complementary sequences were then designed using the 
CRISPR design tool. These target complementary primers act as crRNA in the 
CRISPR-Cas9 system for the RNA-guided DNA recognition. Along with the Cas9-
expressing plasmid, primers were cloned into a different expression vector and 
delivered into MDA-MB-231 TNBC cell line. Upon establishing stable cell lines, 
specific antibodies for Cas9 would be used to pull down dCas9 with proteins sitting 
at close proximity and identified using the RIME proteomic technique. 
Chapter 4 describes the steps and rationale for interpreting the RIME dataset using 
multiple parameters to identify potential candidates regulating BCL11A. These 
include selecting proteins with nuclear expressions; selecting proteins against a 
database which identifies common contaminants in proteomic studies and against  




Figure 1.9: The mechanism of the RNA interference technique.  
shRNA can be delivered into the cells by transfection or viral transduction. The pre-
shRNA transcript is transcribed by RNA polymerase III called Drosha into mature 
shRNA. It is then transported into the cytoplasm and processed by RNase III Dicer 
into siRNA. The siRNA is then loaded onto RISC, unwinding of the RNA duplex 
result in the anti-sense strand degraded by cellular machineries and the sense strand 
to recognising the target mRNA transcript by complementary base pairing. Upon 
recognition, RISC then cleaves the target followed by degradation by cellular 
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the cancer database to identify proteins which upregulation in TNBC and relations 
with BCL11A. These expressions would then be validated using western blot on a 
panel of breast cancer cell lines; DNA-protein interactions using ChIP and protein-
protein interactions by Co-immunoprecipitation.  
Chapter 5 describes the investigation on the effects of these potential regulators on 








































2.1.1.1 Guide RNA design and cloning into PiggyBac vector 
gRNA sequences targeting specific sites on the human BCL11A gene locus chr2: 
60,684,329-60,780,633 were designed by computational screening using the 
University of California – Santa Cruz (UCSC) genome database browser [117], 
named Sites A and B from now on, and ordered in powder form from Sigma. These 
sequences shown in Table 2.1 were selected based on the following criteria:  
1) H3K27Ac histone mark and 2) hypersensitivity to DNaseI cleavage. The forward 
gRNA primers had CTTG attached at the 5’ end and complementary sequences with 
AAAC at the 3’ end. 1M of each primer was mixed into a 10 µl reaction, incubated 
at 95oC for 5 minutes followed by rampdown at a rate of 0.2oC per second to room 
temperature to form oligos.  
PiggyBac vector, PB-gRNA-BsaI-EF1a-RCB (courtesy of Pentau Liu, Sanger), 
was digested in a 20µl reaction containing 2µl of restriction enzyme BsaI-HF 
(NEB) and 2µl of cutsmart buffer (NEB) at 37oC for 3 hours followed by gel 
electrophoresis. DNA fragments with 9000 base pairs were excised and eluted using 
QIAuick Gel Extraction Kit (Qiagen). 1:1 digested gRNA expression vector and 
gRNA oligos, 1µl of T4 DNA ligase (NEB) and 1µl of T4 DNA ligase buffer (NEB) 
were mixed to form a 10µl reaction mixture and incubated at room temperature for 
2 hours. 5µl from the ligation reaction were used to transform NEB 10-beta 
Competent Escherichia coli (E.coli) (NEB). Colonies were picked and 5-10µl of 
bacterial culture was extracted using QIAprep Spin Miniprep Kit  (Qiagen). Oligo 
insertions were then confirmed by double digestions using restriction enzymes 
NotI-HF (NEB) and HpaI (NEB). 
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Primers Sequences 
Site A forward CTTG CGGTGGTGAGATGACCGCCT CGG 
Site A complementary AAAC CCGAGGCGGTCATCTCACCACCG 
Site B forward CTTG GAGAGGTCCACGAGCCACGC AGG 
Site B complementary AAAC CCTGCGTGGCTCGTGGACCTCTC 
Table 2.1: The gRNA sequences designed for targeting BCL11A with dCas9 
The sequences used as gRNAs against Sites A and B for the plasmid, PB-gRNA-
BsaI-EF1a-RCB, are shown with CTTG at the 5’ and AAAC at the 3’ ends followed 
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2.1.1.2 Knocking-out BCL11A with CRISPR-Cas9 vectors 
Primers targeting Sites A and B of human BCL11A were designed by computational 
screening using the UCSC genome database browser and ordered in powder form 
from Sigma. The forward gRNA primers had CACC attached at the 5’ end and 
complementary sequences with AAAC at the 3’ end. These primer sequences are 
shown in Table 2.2. 5µl of forward and complementary primers were annealed 
together at 95oC for 3 minutes followed by rampdown to 22 oC at the rate of 0.1oC 
per second.  
The CRISPR-Cas9 vectors px458 and px459, pSpCas9(BB)-2A-GFP (Addgene) 
and pSpCas9(BB)-2A-Puro (Addgene), respectively, were digested in a 20µl 
reaction with 2µl of BbsI (NEB) and 2µl of Buffer 1.1 (NEB) at 37oC for 1.5 hours. 
DNA fragments with 9000 base pairs were excised after gel electrophoresis and 
extracted using QIAuick Gel Extraction Kit. Next, 4µl of digested vector were 
incubated with 4µl of annealed oligo, 1µl of T4 DNA ligase (NEB) and 1µl of T4 
DNA ligase buffer at room temperature for 2 hours. 5µl from the ligation reaction 
were used to transform NEB 10-beta competent cells. Colonies were picked and 5-
10µl of bacterial culture was extracted using QIAprep Spin Miniprep kit. Positive 
clones were checked by double enzyme digestions using BbsI (NEB) and AgeI 
(NEB).  
2.1.1.3 Designing shRNA primers and cloning into PiggyBac vector 
shRNA primers in Table 2.3 were obtained from MISSION® shRNA (Sigma) 
(https://www.sigmaaldrich.com/life-science/functional-genomics-andrnai/shrna/ 
individual-genes.html) [118] and ordered in powder form from Sigma. 0.1M of 
each primer was mixed into a 20µl reaction with 2µl of T4 ligase buffer (NEB) and 
1µl of T4 PNK enzyme (NEB), incubated at 37oC for 1 hour for phosphorylation 
and then inactivated at 65oC for 20 minutes. 5µl of each complementary primer 
pairs were then annealed together at 95oC for 3 minutes followed by rampdown to 
22oC at the rate of 0.1oC per second.  
The Piggybac shRNA vector, PB-PGK-GFP-Neo-HI (Modified and used by our  
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Primers Sequences 
Site A gRNA 1 forward CACC GTCTCCCTCCCACAAACTGG 
Site A gRNA 1 complementary AAAC CCAGTTTGTGGGAGGGAGAC 
Site A gRNA 2 forward CACC GAGCAGCGGGGAGACCACGG 
Site A gRNA 2 complementary AAAC CCGTGGTCTCCCCGCTGCTC 
Site A gRNA 3 forward CACC GGGGCTTTTACTTCGGCCCC 
Site A gRNA 3 complementary AAAC GGGGCCGAAGTAAAAGCCCC 
Site B gRNA 1 forward CACC GGCTTACAGATGACGCTCTG 
Site B gRNA 1 complementary AAAC CAGAGCGTCATCTGTAAGCC 
Site B gRNA 2 forward CACC GGGGTTCCAAACCAGGGCAG 
Site B gRNA 2 complementary AAAC CTGCCCTGGTTTGGAACCC 
Site B gRNA 3 forward CACC GTAAAACCCTTTCACTCATA 
Site B gRNA 3 complementary AAAC TATGAGTGAAAGGGTTTTAC 
Table 2.2: The gRNA sequences designed for knocking out Sites A and B. 
The forward and complementary sequences used in the CRISPR-Cas9 vectors, 
px458 and px459, for knocking-out corresponding regions of Sites A and B. 
Forward primer was attached with CACC at the 5’ and complementary with AAAC 
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Primers TRC Number Sequences 
Scrambled sequence forward GATCCCTAAGGTTAAGTCGCCCTCGCTC 
GAGCGAGGGCGACTTAACCTTAGG 
Scrambled sequence reverse TCGACCTAAGGTTAAGTCGCCCTCGCTC 
GAGCGAGGGCGACTTAACCTTAGG 
Human DEK  










Human DEK  





















Human PSIP1  










Human PSIP1  










Table 2.3: The shRNA sequences obtained for candidates knock-down 
gRNA sequences for knocking-down the three proteins were obtained from Sigma 
and the scrambled sequences as a control. 
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group, refers to [74]), was digested in a 20µl reaction with 2µl of Xho1 (NEB), 2µl 
of BglII (NEB) and 3µl of Buffer 3.1 (NEB) at 37oC for 2 hours followed by the 
addition of 1µl of CIP (NEB) and incubated at 37oC for 30 minutes. Reactions were 
then run on agarose gel, after which DNA fragments with 6000 base pairs were cut 
out and extracted using QIAuick Gel Extraction Kit. 0.1µg of digested vectors was 
ligated with 6.5µl of annealed primers, 1µl of T4 ligase (NEB) and 1µl of T4 ligase 
buffer (NEB) in a 10µl reaction and incubated at room temperature for 2 hours. 5µl 
from the ligation reaction were used to transform NEB 5α Competent E.coli (NEB). 
Colonies were picked and 5-10µl of bacterial culture was extracted using QIAprep 
Spin Miniprep kit. Oligo insertions were determined by double digestions using 
restriction enzymes EcoRV-HF (NEB) and MluHF (NEB).  
2.1.2 Tissue culture techniques 
2.1.2.1 Culturing cell lines 
Media and culture conditions for cell lines used are summarised in Table 2.4. They 
were either cultured with Dulbecco’s modified Eagle’s medium (DMEM, 
Invitrogen), DMEM: Nutrient Mixture F-12 (DMEM/F12, Invitrogen), Rosewell 
Park Memorial Institute 1640 medium (RMPI, Invitrogen) or Ham’s F12 Nutrient 
Mixture (Ham/F12) was supplemented with fetal bovine serum (FBS, Fetaclone III, 
Clonetech) and Penicillin Streptomycin (PS, Gibco) or Penicillin Streptomycin 
Glutamine (PSG, Gibco). Cells were maintained in a humidified incubator at 37 oC 
and 5% CO2 level throughout.  
2.1.2.2 Cell transfections 
MDA-MB-231 cells (ATCC) were transfected with a total of 5µg vectors using 
Lipofectamine (Life technologies) in Table 2.5. Transfected cells were maintained 
in a humidified incubator at 37oC and at 5% CO2 level for 48 hours. In the 
experiment expressing dCas9, Doxycycline (Clonetech) was used to induce the 
expression for 24 hours and cells were then selected by antibiotics.  
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Cell line Medium Supplements 
MDA-MB-231 DMEM 10% FBS, 1% PSG 
MDA-MB-157 DMEM 10% FBS, 1% PSG 
HCC1569 RPMI 15% FBS, 1% PS 
BT549 RPMI 10% FBS, 1% PSG 
MCF10A DMEM/F12 10% FBS, 1% PSG, 0.2% EGF, 0.5% 
Hydrocortisone, 0.1% Cholera Toxin,  
1% Insulin 
MCF7 DMEM 10% FBS, 1% PSG 
T47D RPMI 10% FBS, 1% PSG 
SUM159T Ham/F12 10% FBS, 1% PS, 0.1 Gentamicin,  
5µg/ml Insulin, 1µg/ml Hydrocortisone 
HS578T DMEM 10% FBS, 1% PSG 
HMLER DMEM 10% FBS, 1% PSG 
Table 2.4: Summary of the culture conditions for the breast cancer cell lines 
used 
The medium and supplements used for the breast cancer cell lines in this project is 
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for 7 days 
2.5µg Catalytically dead 









for 5 days 
shRNA knock-
down candidates 




(Gibco) for 7 
days 
0.5µg Transposase 
Table 2.5: Summary of cell transfections performed 
The conditions for cell transfections in the three experiments mentioned above are 
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2.1.2.3 Proliferation assay 
2000 cells of MDA-MB-231 transfected with shRNA plasmids were seeded. Cells 
were then washed with Phosphate-buffered saline (PBS) twice, trypsinised with 
Trypsin for 5 minutes at 37oC and diluted with normal media to a total of 5ml. 10µl 
were pipetted into a cell counter and cells were counted every 2 days for 14 days. 
Each time-point was performed in triplicate. 
2.1.2.4 Colony forming assay 
MDA-MB-231 cells transfected shRNA plasmids were washed with PBS twice, 
typsinised with Typsin (Invitrogen) for 5 minutes at 37oC and diluted with normal 
media to a total volume of 5ml. Cells were then filtered with 0.22µm filter (Millex) 
and 10µl were pipetted into a cell counter. 2000 cells were aliquoted into Eppendorf 
tubes, centrifuged at 400G for 5 minutes and supernatant removed. Next, 280µl of 
Matrigel (Corning) were added into the Eppendorf tubes on ice and cells were 
resuspended. 70µl of cell-Matrigel mixture were pipetted into a 6-well; this was 
performed in triplicates and 6-well plates were incubated at 37oC, 5% CO2 for 15 
minutes to allow the Matrigel to solidify. 2ml of growth media were added and 
pictures were taken every 2 days from day 5. Images were overlapped with 
Photoshop and the number of colonies was counted with ImageJ.  
2.1.3 Reverse transcriptase (RT)- polymerase chain reaction (PCR) 
RNA was extracted with RNeasy Mini kit (Qiagen) following manufacturer’s 
protocol and quantified with nanodrop. 1-2µg samples were made up to a 11µl 
mixture with 2 µl Random hexamer (Promega) and Nuclease-free water (Qiagen). 
Mixtures were then incubated at 65oC for 5 minutes followed by 5 minutes on ice. 
7µl of mastermix consisting of 0.5µl RT (Roche), 4µl 5xRT Buffer (Roche), 0.5µl 
RNasin (Promega) and 2µl 10mM dNTP (NEB) were added into the RNA mixture 
and cycled at 25oC for 10 minutes followed by 42oC for 10 minutes and lastly at 
70oC for 10 minutes. Finally, complementary DNA (cDNA) was diluted to 50µl 
with Nuclease-free water.  
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To perform quantitative polymerase chain reaction (qPCR), 2µl of cDNA were used 
per reaction. GoTaqÒ kit (Promega) and SYBRTM Select Master Mix 
(ThermoFisher) were used to measure gene expressions in samples. For reactions 
using the GoTaqÒ kit, mixtures were made up with 10µl of TaqMan solution, 1µl 
of probe for specific gene expressions, 2µl cDNA samples and 7µl Nuclease-free 
water in 96-well plates. Reactions with SYBR Green were made up with 10µl 
SYBR Green solution, 1.2µl primer pairs for specific gene expressions, 2µl cDNA 
samples and 6.8µl Nuclease-free water in 96-well plates. They were then placed 
into StepOnePlus Real-Time PCR machine and software (Applied Biosystems). 
Table 2.6 shows the genes of probes used for the qPCR experiments. 
2.1.4 Protein extraction 
Cells were grown in a confluent 6-well, washed with PBS twice and completely 
removed. 60µl of Radioimmunoprecipitation assay (RIPA) buffer (Cell Signalling 
Technology, CST) and 1x Protein inhibitor cocktail (Roche) were added and 
incubated on ice for 5 minutes. Cells were then scraped using a scraper 
(ThermoFisher), pipetted into an Eppendorf tube and a 27 gauge needle (Terumo) 
is used to shear the nuclei. Lysates were then incubated on ice for 30 minutes with 
brief vortexing every 10 minutes and centrifuged at 14,000G, 4oC for 10 minutes. 
Supernatant were transferred into a new Eppendorf tube and cell pellet discarded. 
Protein concentrations were determined with Pierce BCA kit (ThermoFisher) 
following manufacturer’s protocol.  
2.1.5 Western blot 
Whole cell lysates were prepared with lysis buffer (RIPA) buffer and Protein 
inhibitors cocktail. Mixtures of 50µg protein samples, RIPA buffer and reducing 
loading buffer (X4 Laemmli buffer, Bio-Rad, 0.1M Dithiothreitol (DTT), Sigma) 
were heated at 95oC for 10 minutes and proteins were separated in acrylamide gels. 
Table 2.7 shows the composition of acrylamide gels used. Proteins in the gel were 
transferred onto Polyvinylidene difluoride (PVDF) membranes (Carl Roth) at 
400mA for an hour. The membrane was washed with Tris-buffered saline (TBS)- 
Tween 20 (TBS-T) buffer (TBS buffer, 0.1% Tween-20, Sigma) once and blocked  
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Genes Primers Assay ID / Sequences Manufacturer 
Human BCL11A Hs00256254_m1 ThermoFisher 
Human 
DEK 









Forward AAAACAGGGGTTACTTCAACCTC Sigma 
Complementary GGCCTTTCAGCATATTCCTTCT 
Human GAPDH Hs02758991_g1 ThermoFisher 
Human 
PPP2R2D 
Forward GGCAACGACTTCCAGTGGT Sigma 
Complementary ATGAGGGCGGCTTTTATTCTC 
Table 2.6: List of the expression of genes quantified in RT-qPCR 
The Assay ID or primer sequences and manufacturer for genes quantified in RT-
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Percentage of gels Component Volume 
4% Stacking gel 30% Acrylamide (BioRad) 830 µl 
0.5M Tris-HCl, pH 6.8 (Merck) 630 µl 
10% SDS (To be filled in) 50 µl 
10% Ammonium per sulphate (Sigma) 50 µl 
TEMED (Sigma) 5 µl 
Deionised water 1ml 
6% Resolving gel 30% Acrylamide 2 ml 
1.5M Tris-HCl, pH 8 (Merck) 2.5 ml 
10% SDS 100 µl 
10% Ammonium per sulphate 100 µl 
TEMED 8 µl 
Deionised water 5.3 ml 
8% Resolving gel 30% Acrylamide 2.7 ml 
1.5M Tris-HCl, pH 8 2.5 ml 
10% SDS 100 µl 
10% Ammonium per sulphate 100 µl 
TEMED 6 µl 
Deionised water 4.6 ml 
Table 2.7: The components for making Acrylamide gels in western blot 
experiments 
The components and volumes used for the different percentage of Acrylamide gels 
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in 5% non-fat milk powder (Marvel, The Premier Foods Group).  Membranes were 
incubated with primary antibodies, shown in Table 2.8, overnight at 4oC. Rabbit 
and mouse secondary antibodies (GE Healthcare) were probed and proteins were 
detected using Enhanced chemiluminescence (ECL) reagents (GR Healthcare).  
2.1.5.1 Optimising Western blot conditions for antibodies – Protein DEK 
(DEK), Facilitates chromatin transactions (FACT) complex subunit SSRP1 
(SSRP1) and PC4 and SFRS1 interacting protein 1 (PSIP1) 
Optimisations have to be done for the primary antibodies for DEK, SSRP1 and 
PSIP1 prior to incubating with the western blots. The dilutants, 5% Milk or 5% 
Bovine serum albumin (BSA), used to dilute DEK, SSRP1 and PSIP1 primary 
antibodies were first optimised in HEK 293 cells, while keeping their concentration 
consistent. Figure 2.1 shows the resulting blots. DEK and PSIP1 primary antibodies 
work best when diluted with 5% Milk and SSRP1 primary antibodies with 5% BSA. 
2.1.6 RIME 
Cell culture of MDA-MB-231 was expanded to 240x106 cells in complete DMEM 
growth media. Original media were removed, replaced with media containing 1% 
EM-grade formaldehyde (Polysciences) and crosslinked at room temperature for 8 
minutes. Quenching was then performed using a final concentration of 1M Glycine 
solution. Cells were washed twice with ice-cold PBS (Life technology), harvested 
in PBS with Protease inhibitors cocktail and pellets collected by spinning down at 
20,000 rcf for 5 minutes at 4oC.  
100µl of Protein G Magnetic beads (ThermoFisher) per immunoprecipitation were 
placed in 1.5ml Eppendorf tubes, washed with 1ml of 5mg/ml BSA in PBS solution 
and removed after being placed on a magnetic stand on ice for three times. Beads 
were resuspended in 500µl of the BSA/PBS solution with 15µg anti-V5 antibody 
(Abcam) or Rabbit IgG (Abcam) control antibody per immunoprecipitation. The 
tubes containing the beads and antibodies were rotated at 10 rpm in the cold room 
at 4oC overnight. 
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Antibodies Species Concentration Manufacturer 
BCL11A Rabbit 1:5000 in 5% Milk Abcam 
Anti-V5 tag Rabbit 1:5000 in 5% Milk Abcam 
DEK Rabbit 1:1000 in 5% Milk Abcam 
SSRP1 Mouse 1:100 in 5% BSA Santa Cruz 
PSIP1 Rabbit 1:250 in 5% Milk Novus 
Tubulin Mouse 1:10,000 in 5% BSA Abcam 
Table 2.8: The antibodies used in western blot experiments 
The species, concentration and manufacturer of the antibodies used in Western blots 
are summarised in Table 2.8.  
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Figure 2.1: Optimisations for the conditions of western blot for primary 
antibodies, DEK, SSRP1 and PSIP1. 
The condition to dilute DEK, SSRP1 and PSIP1 primary antibodies were optimised 
in HEK293 cells and Tubulin used as loading controls. DEK and PSIP1 blots 
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For each sample, nuclear fraction were extracted by resuspending cell pellets in 
12ml LB 1 buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
(HEPES)- potassium hydroxide (KOH) pH 7.5, Invitrogen, 140 mM Sodium 
Chloride (NaCl), Sigma, 1 mM EDTA, Sigma, 10% Glycerol, Sigma, 0.5% 
Tergitol-type NP-40 (NP-40), MP biomedical, and 0.25% Triton X-100, Promega)  
for 10 minutes at 4oC. Cells were pelleted and resuspended in 12ml LB 2 buffer 
(10 mM Tris- Hydrochloric acid (HCl) pH 8.0, Invitrogen, 200 mM NaCl, 1 mM 
EDTA, and 0.5 mM EGTA, Sigma) and incubated for 5 minutes at 4oC. Cells were 
pelleted again and resuspended in 3.6ml LB3 buffer (10mM Tris-HCl pH 8.0, 
100mM NaCl, 1 mM, EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, Sigma, and 
0.5% N-lauroylsarcosine, Sigma, followed by water bath sonication at 4oC for 6 
cycles of 30 seconds on, 30 seconds off. 30µl of 10% Triton X-100 was added to 
the samples and centrifuged for 10 minutes at 20,000 rcf to remove debris from 
lysate. The supernatant was incubated with antibodies-coated beads and rotated at 
10 rpm in the cold room at 4oC overnight. On the following day, beads were washed 
ten times with RIPA buffer (50mM HEPES-KOH pH 7.6, 1mM 
Ethylenediaminetetraacetic acid (EDTA), 0.7% Sodium-deoxycholate, 1% NP-40, 
0.5M Lithium Chloride, Sigma) and twice with 100mM ammonium hydrogen 
carbonate (AMBIC, Sigma). After the second AMBIC wash, beads were transferred 
into new Eppendorf tubes. Mass spectrometry analyses were performed at the 
proteomics facility at CRUK, CI.  
2.1.6.1 Optimising sonication and determining reverse crosslinking conditions 
2.1.6.1.1 MDA-MB-231 cells 
Chromatin was sheared by sonication with a bioruptor pico at a rate of 30 seconds 
on, 30 seconds off per minute per cycle. Initial trial of sonication took 12 and 15 
cycles with DNA purified with RNaseA (Roche) and Proteinase K (ThermoFisher) 
prior to reverse cross-linking with 5M NaCl at 65oC overnight, presented in Figure 
2.2 A. The size of sonicated fragments was then determined on agarose gel. It was 
seen in Figure 2.2 A that the board smear which was far from the optimised 
sonicated fragments visualised as 200-400bp suggest uneven chromatin shearing 
and sonication was changed to a stronger bioruptor. 1 cycle from the new bioruptor 
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was equivalent to 6 cycles in previous optimisations. However, changing this step 
meant new optimisations of condition were required. The new sample in Figure 2.2 
B was sonicated for 3 cycles and reverse-crosslinked for an hour at 65oC. However, 
the unity of the size of chromatin sheared remains problematic for determining the 
optimised conditions. This was resolved by sonicating samples in Diagenode tubes 
rather than normal Eppendorf tubes. Figure 2.2 C tested 6 cycles of sonication and 
shearing was visualised in the dilutions of 1:8, 1:4 and 1:2. The uniform and optimal 
band sizes visualised in all of the dilutions suggest sonicating samples for 6 cycles 
is the optimal condition and was used for the real sonication. 
2.1.6.1.2 HCC1569 cells 
Optimisation of sonication was repeated with HCC1569 cells. Cells were collected 
and a range of sonication cycles were tested. DNA was then purified with RNaseA 
and Proteinase K before reverse crosslinking at 65oC for an hour. Samples in Figure 
2.2 D show the range of cycles tested. Among them, chromatin sheared with 7 
cycles showed optimal fragment sizes of 200-400 base pairs and was taken forward 
for the real sonication. 
2.1.7 Chromatin Immunoprecipitation 
MDA-MB-231 or HCC1569 cells were expanded to 8.8x106 cells in complete 
DMEM or RPMI growth media. Original media was removed and replaced with 
media containing 1% EM-grade formaldehyde (Polysciences) and crosslinked at 
room temperature for 10 minutes. Fixed cells were then quenched using a final 
concentration of 0.125M Glycine solution. Next, cells were washed twice with ice-
cold PBS (Life technology), harvested in PBS with Protease inhibitors cocktail and 
pellets collected by spinning down at 20,000rcf for 5 minutes at 4oC.  
20µl of Protein G Magnetic beads per immunoprecipitation were placed in 1.5mL 
Eppendorf tubes, washed with 500µl of 5mg/ml BSA in PBS solution and removed 
after being placed in a magnetic stand on ice for three times. Beads were then 
resuspended in 250µl of BSA/PBS solution with 2.5µg Anti-V5 (Abcam); DEK  




Figure 2.2: Optimising sonication and determining reverse crosslinking 
conditions for MDA-MB-231 and HCC1569 cells 
Agarose gel in (A), 12 or 15 cycles and reverse-crosslinked at 65oC overnight. 15 
cycles sonication produced more intense and longer smear, shifted from 2000-
5000bp to 600-5000bp. (B) 3 cycles and reverse-crosslinked at 65oC for 1 hour. 
Smear of 2000-4000bp was observed. (C) 6 cycles sonication and reverse-
crosslinked at 65oC for 1 hour. Uniform sheared fragments between 200-400bp was 
observed. (D) HCC1569 cells sonicated in 4-9 cycles and reverse-crosslinked at 
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(Abcam); SSRP1 (Santa Cruz); PSIP1 (Novus); or 2.5µg controls of Rabbit IgG or 
Mouse IgG (Cell signalling) antibodies per immunoprecipitation. The tubes 
containing the beads and antibodies were rotated at 8 rpm in the cold room at 4oC 
overnight. 10mM 0.5M EDTA, 1% SDS) or 25µl of input sample with 75µl elution 
buffer and incubated at 65oC overnight, vortexing every 5 minutes for the first 15 
minutes. On the following day, supernatant was transferred into new tubes and 
reverse crosslinked  with first, 1µl of RNaseA at 37oC for 30 minutes and second, 
1µl Proteinase K at 55oC for 2 hours. DNA was then eluted with MiniElute Kit 
(Qiagen) following manufacturer’s protocol and quantified with qPCR.  
For each sample, nuclear fractions were extracted by resuspending cell pellets in 
1ml LB 1 buffer for 10 minutes at 4oC. Cells were pelleted and resuspended in 1ml 
LB 2 buffer and incubated for 5 minutes at 4oC. Cells were pelleted again and 
resuspended in 300µl LB 3 buffer followed by water bath sonication at 4oC for 7 
cycles of 30 seconds on, 30 seconds off. 30µl of 10% Triton X-100 was added to 
the samples and centrifuged for 10 minutes at 20,000 rcf to remove debris from 
lysate. The supernatant made 700µl RIPA (50mM Hepes KOH, Invitrogen, 500mM 
8M LiCl, 1mM 10% NP-40, MP biomedical, and 0.7% Sodium-deoxycholate, 
Sigma), once with 700µl Tris-EDTA (TE)/NaCl buffer and spin to remove residual 
buffer. Beads were resuspended in 100µl elution buffer (50mM 1M Tris HCl, 
10mM 0.5M EDTA, 1% SDS) or 25µl of input sample with 75µl elution buffer and 
incubated at 65oC overnight, vortexing every 5 minutes for the first 15 minutes. On 
the following day, supernatant was transferred into new tubes and reverse 
crosslinked  with 1µl of RNaseA at 37oC for 30 minutes and next 1µl Proteinase K 
at 55oC for 2 hours. DNA was then eluted with MiniElute Kit (Qiagen) following 
manufacturer’s protocol and quantified with qPCR.  
To perform qPCR, 2µl of samples were used per reaction. SYBRTM Select Master 
Mix (ThermoFisher) was used to test the specificity of ChIP. Reaction mixtures 
were made up of 10µl of SYBR Green, 1.2µl of primer pair, 2µl cDNA samples 
and 6.8µl Nuclease-free water in 96-well plates. 96-well plates were placed into 
StepOnePlus Real-Time PCR machine and software (Applied Biosystems). Table 
2.9 shows primers used to test the specificity of ChIP experiments. 
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Primers Sequences 
Primer 1 forward ACACCCAGGAGCCAGCAG 
Primer 1 complementary TGTGTGCATTAAAGAGACAGGG 
Primer 2 forward AAGCAGACCAGCTCAAGTGAA 
Primer 2 complementary GCGTACACAGCTTTCTTTCCT 
Primer 3 forward TGTTAAACCAGCCTTGGAGTCA 
Primer 3 complementary TCACTATTGTTACCTGAAGGGG 
Primer 4 forward GGAAATCCAGACCTTGGCAGT 
Primer 4 complementary GGGTGAGCCTGCGGTTATTG 
Table 2.9: The primer sequences used in ChIP-qPCR experiments 
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3.1 Introduction 
The breast cancer subtype triple-negativebreast cancer (TNBC) is the focus of this 
study. It shows clinical characteristics of a higher mortality rate and more frequent 
recurrence within five years than are found with other subtypes [42]. In addition, 
this subtype does not express hormonal receptors for Oestrogen, Progesterone or 
the Human epidermal growth factor receptor 2 (HER2). The lack of these receptors 
in TNBC patients leads to their ineligibility for treatments that have been developed 
to target these receptors, leading to a poor clinical outcome. Therefore, there is an 
urgent need to find new molecular targets so that these patients can be treated. 
One of the advances in the study of this subtype of breast cancer was the discovery 
of the B-cell lymphoma/leukaemia 11A (BCL11A) gene as an oncogene [74]. The 
BCL11A gene was found to show high expression in TNBC patients. A previous 
study by our group has shown its importance in the initiation and maintenance of 
tumourgenesis [74]. However, the regulation of this oncogene in TNBC remains 
unknown. On the other hand, the functional roles of BCL11A in other biological 
systems are better understood. It is known that BCL11A is required: during foetal 
development and for cell functions, including g- to b-globin gene switching [62] 
[63] [65]; to regulate axon outgrowth and branching during brain development 
[71][119]; and in the formation of immune cells such as B-cells [66]. Due to the 
importance of BCL11A in these roles, an inhibitor which globally targets BCL11A 
is not desirable, as it would affect normal cell function and even cell survival. One 
way to overcome this problem is to identify specific regulatory pathways of 
BCL11A in TNBC and to develop compounds that target the interactions between 
these regulatory gene networks or protein complexes.  
To investigate this regulation of BCL11A in TNBC, we have employed the clustered 
regularly interspaced palindromic repeats (CRISPR) system, which was originally 
discovered as a defence mechanism for bacteria and archea [89] [90]. This project 
implements a novel design in dCas9 is used instead of the normal Cas9. This 
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enables specific sites of BCL11A to be targeted while avoiding DNA double-strand 
breaks that would otherwise be introduced by normal Cas9.  
The second novelty in this design is the use of dCas9 as a protein to be pulled down 
by specific antibodies. This has enabled the study of transcriptional regulators and 
the identification of those that may have roles in the regulation of BCL11A’s 
expression at our sites of interest.  
Therefore, the studies detailed in this chapter aim to design and evaluate the 
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3.2 Results 
3.2.1 The determination of which BCL11A genomic regions to study and the 
design of guide RNAs for expression plasmids  
To employ the CRISPR-Cas9 system to target specific sites of BCL11A, the design 
of gRNA was first considered. These gRNAs are responsible for the guidance of 
dCas9 to the BCL11A sites of interest. The sequences of the human BCL11A 
messenger RNA (mRNA) transcript 1 were obtained from the University of 
California Santa Cruz (UCSC) genome browser (Accession number: NM-022893) 
[117]. The UCSC genome browser is an open-access tool available to search for 
annotated genomic sequence data [120]. Through the use of this tool, the sites of 
BCL11A with active transcription based on the annotations represented by the 
H3K27Ac histone marker and sensitivity to DNaseI were identified. The H3K27Ac 
histone marker was used to distinguish between active and inactive gene regions 
[121], while sensitivity to DNaseI indicated regions to which transcription factors 
could bind [122]. These features pinpointed sites with potential active transcription. 
The positions of these genetic sites of interest at the 5’ and 3’ regions are shown in 
Figure 3.1, and they are known in this study as Site A and Site B. The sequences of 
these sites were then used to design gRNAs and their complementary sequences 
using the CRISPR-Cas9 website: http://crispr.mit.edu/ [102]. 
3.2.2 The importance of BCL11A’s genomic targets for cell survival 
To investigate whether the appropriate genomic regions of BCL11A had been 
targeted, plasmids that expressed both gRNA and Cas9 were co-transfected into 
MDA-MB-231 cells. The main reason to perform experiments in this cell line was 
its establishment back in the 1970s [123] and as a standardised cell line for 
researchers to study TNBC. 
The Cas9 was used to delete small fragments of Sites A and B. The positions of 
these gRNAs are shown in Figure 3.2 A. The two plasmids used are shown in Figure 
3.2 B, both of which express Cas9. The plan was that they would each target one 
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gRNA site and guides the Cas9 to these targets, resulting in genome deletion. For 
example, one plasmid might target the gRNA 1 site of Site A while the other might 
target the gRNA 3 site of Site A. Co-transfection of these two plasmids would result 
in the deletion of regions between sites 1 and 3.  
In addition to expressing gRNAs and Cas9, the plasmids also expressed different 
selection markers; one expressed enhanced green fluorescent protein (EGFP) 
signals while the other expressed a puromycin-resistance gene. These markers 
enabled the selection of cells co-transfected with both plasmids, firstly with 
puromycin and secondly by fluorescence-activated cell sorting (FACS) for single 
cells with EGFP expressions. The experimental plan was to identify homozygous 
clones and collect cells to examine their effects on the expression of BCL11A. The 
schematic of this plan is shown in Figure 3.2 C.  
However, transfected cells did not survive the selection by puromycin. The two-
plasmid Cas9 deletion system had been used previously by our group, so the chance 
that cell death was caused by the introduction of plasmids into the cells could be 
ruled out. Possible explanations for the result were that these genomic regions were 
important for the expression of BCL11A, or they affected the downstream pathway, 
and therefore they were detrimental to cell survival. This proved that Sites A and B 
were important and the experiment could proceed.  
3.2.3 The generation of stable cell lines to express gRNAs and dCas9 
After the determination of the importance of the regions of BCL11A to be studied, 
gRNAs whose designs were discussed in section 3.2.1 were cloned into the gRNA-
expression plasmid and transfected alongside the dCas9-expression plasmid into 
MDA-MB-231 cells. The key features of these plasmids are represented in Figures 
3.2 A and B. 
Each gRNA designed with the CRISPR-Cas9 website consisted of short sequences 
of 20 nucleotides followed by a protospacer adjacent motif (PAM) sequence, which 
took the form NGG (a nucleobase followed by two guanine nucleobases). NGG  
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Figure 3.2: Deleting Sites A and B with Cas9 expression plasmids.  
(A) shows positions of primer pairs designed to delete small neighbouring regions 
of BCL11A’s target sites. These sites displayed active transcription shown by the 
histone marker H3K27Ac and hypersensitivity to DNaseI. The red lines are graphic 
representations of target sites – Sites A and B. (B) shows the linearised form of 
plasmids expressing both gRNA and Cas9. gRNA expression was driven by the 
human U6 promoter. In addition, Cas9 was co-expressed either with an EGFP 
fluorescence signal through a self-cleavable 2A protein or with a Puromycin 
resistance gene. (C) shows the schematic of the experimental plan. Cells were first 
transfected with the Cas9 plasmids, followed by puromycin selection and then 
single sort for cells expressing EGFP. Cells will then be collected and the effect on 
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sequences specific for humans [94] were annealed to form primers complementary 
to the sites of interest. These were then cloned into the cloning vector shown in 
Figure 3.3 A. The cloning vectors were supplied by Dr Xuefei Gao of the Sanger 
Institute, Cambridge. Expression was driven by the human U6 promoter. Cells were 
then co-transfected with the dCas9-expression plasmid in Figure 3.3 B. 
The genome transfer was achieved using the PiggyBac (PB) transposon system 
shown in Figure 3.3 C. The enzyme transposase was employed to recognise regions 
of the plasmids that contained inverse terminal repeats (ITR), and to cut and paste 
these into a genomic region with TTAA sequence [124]. This method offered 
simple spatial control. Through the use of this PB gene delivery system, gRNAs 
were expressed with mCherry fluorescence and the blasticidin-resistance gene. 
These features enabled cells that expressed this plasmid to be selected with 
blastocidin followed by FACS. A summary of this experimental approach is shown 
through the use of a schematic in Figure 3.4 A. However, a problem emerged at the 
FACS stage; the percentage of cells that showed double-positive fluorescence 
signals was found to be very low. Therefore, optimisations of this experimental 
approach were needed.  
The schematic for the new experimental plan is shown in Figure 3.4 B. Through 
use of a similar method to that shown in Figure 3.4 A, cells were first transfected 
with gRNA-expression plasmid followed by blasticidin selection and FACS for 
cells that expressed gRNA. These were represented by the mCherry fluorescence 
signal. Next, these cells were transfected with the dCas9-expression plasmid. As 
was observed in the case of the gRNA-expression plasmid, this dCas9 plasmid also 
showed an EGFP fluorescence signal, which enabled the sorting of cells through 
FACS and the generation of stable cell lines that expressed both gRNA and dCas9 
plasmids. The percentages of cells that expressed both plasmids, which were 
produced using the two strategies, were compared. Figures 3.4 C and D are graphs 
comparing the numbers of cells that were double-positive and that expressed gRNA 
for Site A and Site B, respectively. The adoption of this two-step transfection 
system improved the production rate of cells co-transfected with both plasmids 
from 0.04 per cent to eight per cent and six per cent, respectively.   
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Figure 3.3: gRNA- and dCas9-expressing vectors and gene delivery.  
Graphic representations in (A) and (B) show the linearised forms of gRNA- and 
dCas9- expressing plasmids. In the gRNA-expressing plasmid, gRNA expression 
was driven by the U6 promoter. It also expresses the mCherry fluorescence signal 
and rTtA component of the Tet-On system. Meanwhile, multi-tagged dCas9 was 
co-expressed with EGFP signal through a self-cleavable 2A protein in between. It 
also has the TRE component of the Tet-On system to initiate transcription. Both 
plasmids employ the PB transposon and Tet-On system. (C) PiggyBac transposon 
transfer specific vector regions using a cut-and-paste mechanism. The enzyme, 
transposase, recognises and cuts the the inverted terminal repeats (ITR). This 
enables an easy cut-and-paste mechanism for transferring the region of gRNA 
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Figure 3.4: Optimisations of co-transfections. 
The schematics of transfections are shown in (A) and (B). (A) shows the 1-step 
experimental plan where MDA-MB-231 cells were first co-transfected with both 
plasmids followed by Blastocidin selection and sort for cells which are double-
positives. (B) shows the new schematic of the experimental plan. Cells are now 
transfected with firstly gRNA-expression plasmids, followed by Blastocidin 
selection and sort for cells with mCherry. Next, these cells are transfected with the 
dCas9-expression plasmid and sorted for double-positives. (C&D) describe the 
comparison of cells with double-positives from the two schemes. (C) are cells with 
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3.2.4 The validation of the induction and expression of dCas9 using the Tet-
On system 
The transposon system was used for stable gene delivery, while the Tet-On system 
was employed to induce dCas9 expression with Doxycycline. This was achieved 
by including a component of the Tet-On system [126], the recombinant 
tetracycline-controlled transcription factor (rTtA), in the gRNA-expression plasmid 
in addition to gRNA, the mCherry fluorescence signal and the blasticidin-resistance 
gene. This rTtA is normally inactive but constitutively expressed in the cells. 
Activation only occurs when Tetracycline or its derivative, Doxycycline, is 
introduced into the culture medium. The activated rTtA protein then binds to the 
Tet response element (TRE) in the dCas9-expression plasmid, and this enables 
temporal control of the expression of dCas9.  
3.2.4.1 Determination that dCas9 is inducible and its impact on BCL11A 
expression investigated 
The fluorescence signals in the expression plasmids enabled the expression of 
gRNA and dCas9 to be validated. The results are shown in Figure 3.5 A. The EGFP 
from the dCas9-expression plasmid was expressed at the same time as the protein 
and then separated shortly afterwards through the use of a self-cleavable 2A protein. 
To assess whether this co-expression system was functional, RNA and proteins 
were collected to perform a qPCR and western blot analysis, respectively. The 
western blot shown in Figure 3.5 B indicated that cells had been co-transfected with 
the gRNA- and dCas9-expression plasmids. Anti-V5 tag antibody was used against 
the V5 from the multi-tagged dCas9, and tubulin was employed as a loading control. 
The level of dCas9 observed in the non-induced samples was measured to provide 
a background level. Inductions were clearly seen in the samples that contained Sites 
A and B. Thus, as expected, inducing the expression of dCas9 protein with 
Doxycycline correlated with the observed levels of EGFP. 
After validating the expression of dCas9, it was necessary to determine whether this 
induction affected the expression of BCL11A. Data obtained from qPCR analysis, 
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shown in Figure 3.5 C, suggested that dCas9 expression did not show any impact 
on the expression of BCL11A at either Site A or Site B. The cells described above 
were collected after 24 hours of Doxycycline induction. To determine whether 
increased time of exposure to Doxycycline would affect expression of BCL11A, the 
duration of the dCas9 induction experiment was extended to 48 hours. The result is 
illustrated in Figure 3.5 D and shows that the expression of dCas9 did not affect the 
expression of BCL11A regardless of the duration of induction. This indicates Cas9 
bind close to Sites A and B but does not obstruct access of transcription factors to 
these sites that regulates BCL11A’s expression.  
3.2.5 Determination that dCas9 binds specifically at its corresponding targets 
In addition to validating the expressions of the plasmids, it was important to validate 
the specificity of the binding of dCas9 using ChIP coupled with qPCR. In the ChIP 
experiment, samples that were not subjected to Doxycycline induction were used 
to provide background data, while samples pulled down with IgG antibody instead 
of dCas9 were employed as a control. In the qPCR step, two primers specific for 
Sites A and B were also used. These were named primer 1 and primer 2 and their 
positions on BCL11A are shown in Figures 3.6 and 3.7. Using these primers, dCas9 
was found to be bound at both target sites shown in Figures 3.6 B and 3.7 B. The 
specificity of dCas9 was also confirmed through the use of opposite primers as non-
specific controls: that is, primer 2 was used for samples with gRNA for Site A and 
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3.3 Discussion 
This chapter has described the design of gRNA for the CRISPR-Cas9 system and 
the experimental method used to target particular genetic regions. Specific genomic 
regions on the BCL11A gene that displayed active transcriptional regulation were 
selected for the gRNA design. These gRNAs were then cloned into gRNA-
expression plasmids, which guided dCas9 to bind to their corresponding targets. 
Plasmids were co-transfected into MDA-MB-231 cell lines; the expression of 
dCas9 and its specificity regarding its ability to bind to target sites was then 
validated. 
3.3.1 The evaluation of the importance of chosen target sites 
The sites of interest on BCL11A, which have been designated as Sites A and B, 
were chosen because of their strong regulation of transcription as displayed in the 
UCSC genome browser [117]. This was represented by their activity towards the 
H3K27Ac histone marker [121] and their sensitivity to DNaseI [122]. To 
investigate if these target sites were indeed important for expression of BCL11A, 
Cas9 was used to delete Sites A and B. However, the cells did not survive the initial 
deletion of the whole genetic regions. To overcome this problem, deletion of 
smaller fragments within the regions was employed, to investigate whether any 
regions within Sites A and B played a major role in the regulation of the expression 
of BCL11A. However, the cells also did not survive this experiment after puromycin 
selection. This led to the conclusion that these target regions might be important for 
gene expression, or the deletions affected the downstream pathway and thus were 
detrimental to cell survival.  
3.3.2 The validation of components of the experimental design 
After establishing the importance of the regions to be studied, cloning was resumed 
of the designed gRNA into the gRNA-expression plasmid. The altered plan to 
transfect separately the gRNA- and dCas9-expression plasmids significantly 
increased the percentage of cells that expressed both plasmids. Once the 
components of the experimental design had been validated, such as dCas9 
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expression and its binding specificity, these cell lines were expanded in cell cultures 
and fixed by formaldehyde for the RIME experiment described in Chapter 4.  
I attempted to expand this work beyond the identification of transcriptional 
regulators for BCL11A in TNBC to generate stable cell lines for other breast-cancer 
subtypes such as MCF7 and T47D. However, the cells did not survive blasticidin 
selection or were not transfected. This was demonstrated by the very small number 
of cells collected during the FACS stage.  
A key component of the experimental design that required validation was the PB 
transposon system. The mCherry and EGFP fluorescence signals showed in Figure 
3.5 A suggested that gene delivery by this system was successful. The protein level 
of dCas9 expression was also examined by the use of western blots. The western 
blot displayed in Figure 3.5 B indicated successful induction of dCas9 by the 
introduction of Doxycycline into the culture medium used in the Tet-On system.  
As well as the validation of the expression of gRNA and dCas9, it was also 
important to investigate whether the induction of dCas9 had any impact on 
expression of BCL11A. This was performed through RT-qPCR experiments. The 
initial induction experiment was performed for 24 hours, during which protein 
lysate were collected at various time-points. No change in the expression of 
BCL11A was observed after induction of dCas9 expression at both Sites A and B. 
This effect was also seen when the duration of induction was extended to 48 hours.  
The final evaluation required of this CRISPR-Cas9 system was of the specificity of 
dCas9. V5-tagged antibody was used to pull-down multi-tagged dCas9 during ChIP 
experiments. The site of dCas9 binding was then investigated through the use of 
primers specific to Sites A and B during the qPCR step. The data shown in Figures 
3.6 and 3.7 indicated that dCas9 binding was specific upon induction.  
In summary, the experimental design was evaluated and cell lines were generated 
which expressed gRNA for Sites A and B and dCas9 in a stable manner. These cells 
were then prepared for the RIME experiment described in Chapter 4.  
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4.1 Introduction 
RIME is a technique used to study proteomics. It combines ChIP with mass 
spectrometry. The coupling of these two techniques enables the use of RIME to 
study and identify proteins positioned at genomic sites that might regulate BCL11A 
in Triple-negative breast cancer. This process was applied after cells were 
transfected with the adapted CRISPR-Cas9 system as described in Chapter 3. It is 
presented in Figure 4.1.  
The aim of this chapter is to analyse the RIME pull-down and to validate the use of 
this technique by determining whether these proteins are biologically relevant and 
show important functions in the regulation of BCL11A.  
Page | 74 
 
 
Figure 4.1: Experimental work flow for RIME.  
The graphic representation in (A) shows the positions of our target sites, Sites A 
and B, on BCL11A. (B) shows the schematic of the experimental work flow for 
RIME. Cells were first transfected with the CRISPR-Cas9 system, described in 
Chapter 3, and then fixed with formaldehyde and sonicated to shear DNA. Next, 
samples were processed as a ChIP experiment using Anti-V5 antibodies to pull-
down Cas9 itself along with proteins bound in close proximity. These protein 
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4.2 Results 
4.2.1 Formation of a reverse crosslink for RIME to visualise sizes of sonicated 
chromatin 
The establishment of stable cell lines was described in Chapter 3. The number of 
lines was expanded to twleve 15cm plates. These were fixed with formaldehyde to 
crosslink proteins at close proximity and to stabilise interactions [83]. This is an 
important step in order to study protein-protein interactions in designated genetic 
regions. To investigate proteins with the potential to regulate the expression of 
BCL11A, nuclear fractions from the cell pellets were isolated. Chromatin was then 
sheared by sonication. Chapter 2: Materials and Methods provides details of the 
processes and optimisations employed.  
4.2.2 The analysis of protein pull-down from the RIME dataset 
The number of proteins collected during the initial pull-down in RIME was 326 
from Site A and 491 from Site B. These figures were narrowed down using multiple 
parameters to reduce the number of proteins required to be studied, refers to 
Appendix A for the full protein list after each filter. The work flow is shown in 
Figure 4.2.  
Firstly, the RIME experiment was performed in triplicate for each sample and the 
pulled-down proteins were mixed together. The overlapping members of the list of 
proteins pulled down using Anti-V5 antibodies against the multi-tagged dCas9 were 
compared against those pulled down in the control IgG sample, in which the Anti- 
V5 antibody had been replaced with an IgG antibody. Tables 4.1- 4.3 list the top 20 
proteins that remained after this elimination between or from Sites A and B. 
 
Secondly, the list of the remaining proteins was compared with those observed 
between and from the two targets. Proteins in common are shown on the Venn 
diagram in Figure 4.2.  
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Figure 4.2: Interpreting RIME data.  
Average number of proteins pulled down from the triplicates of Sites A and B were 
326 and 491, respectively. Proteins were filtered using various strategies – 
eliminating common proteins from IgG control, number of peptide number plus 
cumulative scores, common proteins between and within samples, expression in the 
nucleus, less than 100 studies from the Crapome database, cBioportal database 
correlating mRNA expression with PAM50, and BCL11A expression. literature 
search for proteins with known roles in breast cancer. 3 potential candidates were 
identified: DEK and SSRP1 from both target sites and PSIP1 from Site B.  
  
RIME data
Average number of protein pull down from 3 repeats in Site A: 326
Average number of protein pull down from 3 repeats in Site B: 491
Filters
Elimination of common proteins from IgG control
Peptide number
Common proteins between and within samples
Cumulative scores
Expression in nuclear compartment
Crapome study: <100 studies
cBioPortal: mRNA expression vs PAM50, correlation with BCL11A expression
 Anti-V5 1  Anti-V5 2
Anti-V5 3




Potential candidates for Sites A and B’: DEK, SSRP1
Potential candidates for Site B only: PSIP1
Literature
Site A Site B
Page | 77 
 
Eliminate from IgG and common between triplicates 
Sites A and B 
UniProt Gene ID Gene name 
P21333 FLNA Filamin-A 
O75369 FLNB Filamin-B 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 
Q13838 DDX39B Spliceosome RNA helicase DDX39B 
P38919 EIF4A3 Eukaryotic intiation factor 4A-III 
O75533 SF3B1 Splicing factor 3B subunit 1 
P13010 XRCC5 X-ray repair cross-complementing protein 5 
O15027 SEC16A Protein transport protein Sec16A 
P11940 PABPC1 Polyadenylate-binding protein 1 
Q9BY77 POLDIP3 Polymerase delta-interacting protein 3 
Table 4.1: Summary of top 20 proteins from the RIME analysis after 
eliminating common proteins between IgG and triplicates between two target 
sites.  
Top 20 proteins between Sites A and B samples are shown, presented in UniProt 
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Eliminate from IgG and common between triplicates 
Site A only 
UniProt Gene ID Gene name 
O00567 POLDIP3 Nucleolar protein 56 
Q9UKM9 RALY RNA-binding protein Raly 
Q8IY81 GBAA_3676 pre-rRNA processing protein FTSJ3 
O60832 DKC1 H/ACA ribonucleoprotein complex subunit 
DKC1 
O43290 SART1 U4/U6.U5 tri-snRNP-associated protein 1 
Q9BY78 RNF26 E3 ubiuitin-protein ligase RNF26 
Q9Y3Y3 SH2B1 SH2B adapter protein 1 
P46014 KAPP Protein phosphatase 2C 70 
Q9Y2X4 SH2D3A SH2 domain-containing protein 3A 
P82980 RBP5 Retinol-binding protein 5 
Table 4.2: Summary of top 20 proteins from the RIME analysis after 
eliminating common proteins between IgG and triplicates at Site A.  
Top 20 proteins in Sites A samples are shown, presented in UniProt ID, gene ID, 
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Eliminate from IgG and common between triplicates 
Site B only 
UniProt Gene ID Gene name 
Q09666 AHNAK Neuroblast differentiation-associated protein 
AHNAK 
Q86V81 ALYREF THO complex subunit 4 
O00148 DDX39A ATP-dependent RNA helicase DDX39A 
P68032 ACTC1 Actin, alpha cardiac muscle 1 
Q9NZM1 MYOF Myoferlin 
P12956 XRCC6 X-ray repair cross-complementing protein 6 
P09651 HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 
P55795 HCRNPH2 Heterogeneous nuclear ribonucleoprotein H2 
P23396 RPS3 40S ribosomal protein S3 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 
Table 4.3: Summary of top 20 proteins from the RIME analysis after 
eliminating common proteins between IgG and triplicates at Site B.  
Top 20 proteins in Sites B samples are shown, presented in UniProt ID, gene ID, 
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The Venn diagrams show the number of proteins that overlapped between two or 
three replicates from the same target site. There were 101 proteins pulled down 
from Site A and 224 proteins from Site B. The centre of the Venn diagram shows 
that 70 proteins were identified that were common between the two target sites. It 
also shows the number of unique proteins from each target site: 31 from Site A and 
157 from Site B. The listed proteins were then sorted in descending order by peptide 
number to identify proteins with a unique peptide number of at least one. 
Cumulative scores were then pulled from each list. The peptide number of at least 
one provided confidence that the “correct” protein would be identified from the 
peptide sequences during mass spectrometry. Each protein was also given a score 
in direct correlation with the abundance of the proteins in the samples. Thus, the 
higher the cumulative score, the higher the frequency of detection of that protein 
during mass spectrometry.  
Proteins were also sorted according to their expressions in the cellular 
compartments. Attention was paid to proteins with expression in the nuclear 
compartment, because the aim was to study proteins with the potential to regulate 
expression of BCL11A. Tables 4.4 – 4.6 shows the top 20 proteins after the 
application of this parameter to the process of protein rationalisation. Next, the 
proteins were considered against the Contaminant Repository of Affinity 
Purification (Crapome) database [127]. This online resource was used as a quality 
control to eliminate protein contaminants that had been shown previously to supply 
noise signals in mass spectrometry studies. This procedure raised the quality of the 
analysis as the use of negative control is often insufficient to remove those proteins 
identified as background [127]. Proteins with a score of 100 according to the 
Crapome database were considered to be noise. The top 20 proteins that remained 
after this filtering process are shown in Tables 4.7 – 4.9. 
The proteins that remained on the list were analysed further against the large dataset 
of The Cancer Genome Atlas (TCGA) from the cBioPortal [32]. This dataset 
records the genetic and molecular heterogeneity of breast cancer patients. The 
parameters employed at this filtering step included comparison of the expression of 
mRNA against PAM50 and its correlation with the expression of BCL11A’s mRNA.  
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Nuclear expression 
Sites A and B 
UniProt Gene ID Gene name 
Q9BY77 POLDIP3 Polymerase delta-interacting protein 3 
Q9Y3Y2 CHTOP Chromatin target of PRMT1 protein 
P46013 MKI67 Antigen KI-67 
P82979 SARNP SAP domain-containing ribonucleoprotein 
Q9Y2X3 NOP58 Nucleolar protein 58 
P11388 TOP2A DNA topoisomerase 2-alpha 
Q9Y5S9 RBM8A RAN-binding protein 8A 
Q05519 SRSF11 Serine/arginine-rich splicing factor 
Q13185 CBX3 Chromobox protein homolog 3 
Q9Y5B9 SUPT16H FACT complex subunit SPT16 
Table 4.4: Summary of top 20 proteins from the RIME analysis after filtering 
for proteins with nuclear expressions between two targets. 
Top 20 proteins in Sites A and B samples are shown, presented in UniProt ID, gene 
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Nuclear expression 
Site A only 
UniProt Gene ID Gene name 
O00567 NOP56 Nucleolar protein 56 
Q9UKM9 RALY RNA-binding protein Raly 
Q8IY81 FTSJ3 pre-rRNA processing protein FTSJ3 
O60832 DKC1 H/ACA ribonucleoprotein complex subunit 
DKC1 
O43290 SART1 U4/U6.U5 tri-snRNP-associated protein 1 
Q9BY78 RNF26 E3 ubiuitin-protein ligase RNF26 
Q9Y3Y3 SH2B1 SH2B adapter protein 1 
P46014 KAPP Protein phosphatase 2C 70 
Q9Y2X4 SH2D3A SH2 domain-containing protein 3A 
P82980 RBP5 Retinol-binding protein 5 
Table 4.5: Summary of top 20 proteins from the RIME analysis after filtering 
for proteins with nuclear expressions at Site A. 
Top 20 proteins in Site A samples are shown, presented in UniProt ID, gene ID, 
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Nuclear expression 
Site B only 
UniProt Gene ID Gene name 
Q09666 AHNAK Neuroblast differentiation-associated protein 
AHNAK 
Q9NZM1 MYOF Myoferlin 
P62333 PSMC6 26S proteasome regulatory subunit 10B 
Q96S55 WRNIP1 ATPase WRNIP1 
Q8ND24 RNF214 RING finger protein 214 
O75367 H2AFY Core histone macro-H2A.1 
P04083 ANXA1 Annexin A1 
O00299 CLIC1 Chloride intracellular channel protein 1 
Q86V48 LUZP1 Leucine zipper protein 1 
Q9H0S4 DDX47 Probable ATP-dependent RNA helicase 
DDX47 
Table 4.6: Summary of top 20 proteins from the RIME analysis after filtering 
for proteins with nuclear expressions at Site B. 
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Crapome database (<100 studies) 
Sites A and B 
UniPot Gene ID Gene name 
Q9Y3Y2 Chtop Chromatin target of PRMT1 protein 
P46013 MKI67 Antigen KI-67 
Q9Y2X3 NOP58 Nucleolar protein 58 
P11388 TOP2A DNA topoisomerase 2-alpha 
Q9Y5S9 RBM8A RNA-binding protein 8A 
Q05519 SRSF11 Serine/arginine-rich splicing factor 11 
Q13185 CBX3 Chromobox protein homolog 3 
Q9Y5B9 SUPT16H FACT complex subunit SPT166 
Q08945 SSRP1 FACT complex subunit SSRP1 
P35659 DEK Protein DEK 
Table 4.7: Summary of top 20 proteins from the RIME analysis after referring 
to the Crapome database between Sites A and B. 
Top 20 proteins in Sites A and B samples are shown, presented in UniProt ID, gene 
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Crapome database (<100 studies) 
Site A only 
UniProt Gene ID Gene name 
O00567 NOP56 Nucleolar protein 56 
Q9UKM9 RALY RNA-binding protein Raly 
Q8IY81 FTSJ3 pre-rRNA processing protein FTSJ3 
O60832 DKC1 H/ACA ribonucleoprotein complex subunit DKC1 
O43290 SART1 U4/U6.U5 tri-snRNP-associated protein 1 
Q9BY78 RNF26 E3 ubiquitin-protein ligase RNF26 
Q9Y3Y3 SH2B1 SH2B adapter protein 1 
P46014 KAPP Protein phosphatase 2C 70 
Q9Y2X4 SH2D3A SH2 domain-containing protein 3A 
O75475 PSIP1 PC4 and SFRS-1 interacting protein 
Table 4.8: Summary of top 20 proteins from the RIME analysis after referring 
to the Crapome database at Site A. 
Top 20 proteins in Site A samples are shown, presented in UniProt ID, gene ID, 
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Crapome database (<100 studies) 
Site B only 
UniProt Gene ID Gene name 
Q09666 AHNAK Neuroblast differentiation-associated protein 
AHNAK 
Q9NZM1 MYOF Myoferlin 
Q9BY77 POLDIP3 Polymerase delta-interacting protein 3 
P62333 PSMC6 26S proteasome regulatory subunit 10B 
Q96S55 WRNIP1 ATPase WRNIP1 
P82979 SARNP SAP domain-containing ribonucleoprotein 
Q8ND24 RNF214 RING finger protein 214 
P04083 ANXA1 Annexin A1 
O00299 CLIC1 Chloride intracellular channel protein 1 
Q86V48 LUZP1 Leucine zipper protein 1 
Table 4.9: Summary of top 20 proteins from the RIME analysis after referring 
to the Crapome database at Site B. 
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PAM50 is an assay that classifies intrinsic subtypes through the quantification of the 
co-expression of 50 genes [27]. Only proteins that were found to be highly regulated 
in TNBC were advanced to the next filtering stage. Application of all these 
parameters led to identification of 12 potential protein candidates. The plots of their 
mRNA expressions against PAM50 are shown in Figure 4.3.  
Finally, a literature review was performed to search for proteins with known 
functions in the regulation of transcription or involvement in breast cancer. Three 
proteins were identified from Sites A and B after filtering the lists of RIME pull- 
down proteins against these multiple parameters and resources. These proteins were 
DEK, structure specific recognition protein 1 (SSRP1) and PC4 and SFRS1 
interacting protein 1 (PSIP1).  
4.2.3 The validation of protein pull-down from RIME 
4.2.3.1 The expression of candidates in TNBC cell lines 
To confirm whether DEK, SSRP1 and PSIP1 were abundantly expressed in TNBC, 
protein lysate was extracted from a panel of breast cancer cell lines and their 
quantities determined. Seven TNBC and three Luminal lines were used. They were 
studied by western blot analysis for which conditions for the employed antibodies 
had been optimised. The optimisations were performed with HEK293 cells to 
choose the dilutants for the primary antibodies that would retain consistent 
concentrations. Chapter 2: Materials and Methods provides further details. 
DEK, SSRP1 and PSIP1 were all observed to show greater expression in the TNBC 
cell lines than in the Luminal cell lines. The western blots obtained can be seen in 
Figure 4.4. Tubulin was used as a loading control.  
4.2.3.2 Confirmation by ChIP that the proteins bind at the target sites  
ChIP experiments were performed in MDA-MB-231 wild type cells to determine 
whether DEK, SSRP1 and PISP1 bind at Sites A and B of BCL11A. Antibodies 
specific to each candidate or to the IgG control were used to pull-down proteins.  




Figure 4.3: cBioportal database correlating mRNA expression with PAM50 and 
BCL11A expression.  
Graphs were adapted from the cBioportal database; proteins CHTOP, SSRP1, 
MKI67, ANLN, GTPBP4, DEK, PSIP1, NOP58, ANXA1, MTA2, HMGA1, and 
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Figure 4.4: Protein expression of candidates on a panel of breast cancer cell 
lines.  
A panel of breast cancer cell lines were used. DEK expression is found in all cells 
except MDA-MB-157. SSRP1’s varying expressions were found across the panel. 
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Primers were then used to amplify the targets in the qPCR step to identify the bound 
DNA regions. The ChIP analysis is shown in Figures 4.5. It indicated that DEK, 
SSRP1 and PSIP1 binding was enriched at Sites A and B. Moreover, binding by 
SSRP1 at Site B and by PSIP1 at both target sites reached statistical significance.  
The specificities of protein binding were then assessed by repeating the ChIP 
experiments. Proteins were pulled down as described earlier but with the use of 
different primers during the qPCR step. These primers, which were labelled primers 
3 and 4, were designed to be placed as close as possible to Sites A and B. Their 
positions on the BCL11A gene can be seen in Figure 4.6 A. 
The ChIP data displayed in Figures 4.6 B-D show that the binding of DEK, SSRP1 
and PSIP1 was enriched at neighbouring sites to A and B. Moreover, this binding 
reached statistical significance in the case of SSRP1 at the region next to Site A and 
for PSIP1 at the region adjacent to Site B.  
These ChIP data were also validated in another TNBC cell line, HCC1569. The 
western blot data shown in Figure 4.4 indicated that this cell line had more DEK, 
SSRP1 and PSIP1 expressions than were observed in MDA-MB-231 cells. As 
before, antibodies specific to the candidate proteins or to the IgG control were used 
to pull-down proteins and then their binding was analysed to determine whether 
they were bound at Sites A and B or at neighbouring regions. The data shown in 
Figure 4.7 suggests that binding of DEK, SSRP1 and PSIP1 was enriched at Sites 
A and B. The binding by DEK and SSRP1 at Site A reached statistical significance. 
Finally, an evaluation was performed regarding the specificity of the binding. 
Figure 4.8 shows that DEK, SSRP1 and PSIP1 were bound at sites that lay near A 
and B.  
To summarise: DEK, SSRP1 and PSIP1 bind at Sites A and B and at neighbouring 
sites. 
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Figure 4.5: ChIP experiment results, showing candidates binding in MDA-
MB-231.  
(A) in Figure 4.5 above is a graphic representation of the positions of primers 1 and 
2 on BCL11A. DEK, SSRP1, and PSIP1 bind at both targets but SSRP1 binds 
preferentially at or close to Site B. Samples pulled down with IgG antibody were 
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Figure 4.6: Specificities of candidates’ bindings in MDA-MB-231 cells.  
(A) in Figure 4.6 above is a graphical representation of the positions of primers 3 
and 4 on BCL11A. These are nearby regions of Sites A and B. DEK, SSRP1, and 
PSIP1 bind to both targets, but SSRP1 was observed to bind preferentially to 
regions close to Site A whereas PSIP1 was observed to bind preferentially to Site 
B. Samples pulled down with IgG antibody were used as internal controls and 
graphs are plotted in relation to input. (* <0.05, t-test, n=2-3.) 
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Figure 4.7: ChIP experiment results, showing candidate bindings in HCC1569 
cells.  
(A) in Figure 4.7 above is a graphical representation of the positions of primers 1 
and 2 on BCL11A. All candidate proteins were observed to bind to both target sites, 
but SSRP1 bound preferentially at the 5’ end. Samples pulled down with IgG 
antibody were used as internal controls and graphs are plotted in relation to input. 
(*<0.05, t-test, n=2-3.)  
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Figure 4.8: Specificities of candidate bindings in HCC1569 cells.  
(A)in Figure 4.8 above is a graphical representation of the positions of primers 3 
and 4 on BCL11A. These are the neighbouring regions of Sites A and B. DEK, 
SSRP1, and PSIP1 were observed to bind at both target sites. Samples pulled down 
with IgG antibody were used as internal controls and graphs are plotted in relation 
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4.2.3.3. The evaluation of any bias in target binding by DEK, SSRP1 and PSIP1 
To assess whether DEK, SSRP1 or PSIP1 show binding bias regarding particular 
sites on BCL11A in MDA-MB-231 and HCC1569 cell lines, statistical analysis was 
performed on the results described in section 4.2.3.2. The potential for bias was 
tested between Primers 1 and 2 at Sites A and B; between Primers 3 and 4 at the 
regions near to Sites A and B; and among all four primers. The results are presented 
in Table 4.10.   
Firstly, DEK binding was found to differ between Sites A and B in MDA-MB-231 
cells. This difference was also observed when results were compared across all four 
primers and was therefore further analysed with post-hoc tests. It was revealed that 
Primer 1, at Site A, bound differently to all other primers. Primer 2 was also found 
to bind differently at Site B compared with Primers 3 and 4 at their binding sites. 
Secondly, SSRP1 was found to bind in a similar way to DEK, except that 
differences in binding were also observed between Primers 3 and 4. Post-hoc tests 
showed statistically significant binding differences between Primers 1 and 2 
compared with Primers 3 and 4. In contrast, no differences were found between 
methods of PSIP1 binding at any of the sites studied.  
DEK binding bias was observed to be different in HCC1569 compared with that in 
MDA-MB-231 cells, in that no statistically significant binding difference was 
detected in this cell line between any primers. In contrast, SSRP1 binding 
differences between Primers 1 and 2 were statistically significant, and subsequent 
tests that analysed all four primers also suggested binding differences among them. 
Lastly, the binding bias of PSIP1 was found to be the same as in MDA-MB-231 
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4.3 Discussion 
After the generation of a stable cell line with gRNA- and dCas9-expressing 
plasmids, the numbers of cells were expanded and fixed by formaldehyde. Next, 
sonication was employed for optimisation, followed by immunoprecipitation using 
antibody against the multi-tagged dCas9 to pull-down dCas9 itself and proteins in 
close proximity. Samples were then analysed by mass spectrometry. The positive 
protein findings identified by RIME were based on various criteria, including 
expression of the proteins in the cellular compartments, similarity to BCL11A in 
terms of clinical contribution, and functional properties. Three proteins, DEK, 
SSRP1 and PSIP1, were found to exhibit relationships to the clinical characteristics 
of Triple-negative breast cancer and tumour progression, and some were involved 
in the maintenance of stemness. These findings proved that pulling down proteins 
in relation to breast cancer was feasible through the use of the experimental design 
employed in this study. 
4.3.1 Analysis of RIME pull-down 
Pulled-down proteins have various functions and roles in breast cancer, which are 
summarised in Table 4.11. Their relationship with clinical features and involvement 
in certain processes suggested that the experimental design employed in this study 
was applicable to the investigation of potential protein regulators of BCL11A 
transcription.  
The proteins were first split into peptides with the use of trypsin to perform mass 
spectrometry. Three peptide filters were employed to increase the possibility of 
Correct protein identification. Secondly, the data was rationalised through the 
elimination of proteins against the IgG control and the identification of unique 
proteins present in each sample. Thirdly, the proteins were separated into different 
cellular compartments and only those observed to be from the nucleus were further 
analysed. This was because the focus of the project was to identify putative protein 
regulators for BCL11A. Next, proteins that were expressed in the nucleus were 
analysed using the Crapome database, which provides hints regarding the  
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 DEK SSRP1 PSIP1 
Functions Induce positive DNA 
supercoils [128], 
chromatin organisation 
[129] and selection of 
position for splicing 
[130] 
Subunit of the FACT 
complex and is 
required for 
transcription  [131], 
as co-activator of 

















Prognostic marker for 
survival [137]; 
involves in metastasis 
[138] [139], 
mammosphere 








poor prognosis [140] 
[141] [142]; involves 





to survival, regulates 
cell cycle gene 
expression , involves 
in migration and 
invasion [144] 
Table 4.11: Summary of known cellular functions and roles in breast cancer.  
These factors identified from RIME are involved in different roles in the cells. 
Some were also identified to be useful as prognostic markers and are involved in 
different functions in breast cancer.  
 
 
Page | 99 
 
background proteins that are commonly identified from mass spectrometry 
experiments [127]. Comparison with this data enabled further rationalisation to 
continue the study only with those proteins that showed higher potential for success 
related to the project aim. Lastly, proteins were identified according to their clinical 
contributions to breast cancer subtypes. This was achieved using the PAM50 
analysis from the TCGA dataset. Application of these filters identified proteins 
DEK, SSRP1 and PSIP1, which were seen only in samples pulled down using Anti-
V5 antibody with expressions in the nucleus and upregulated in the TNBC subtype. 
These proteins were analysed further based on their cellular functions.  
To investigate whether DEK, SSRP1 and PSIP1 showed greater expression in cell 
lines, as stated in the cBioportal database, a panel of breast cancer cell lines was 
collected and proteins lysate were extracted to perform western blot analysis.  
DEK was originally identified as a gene involved in acute myeloid leukaemia 
(AML) [145]; in chromatin organisation [129]; in tumour progression [138] [139]; 
in the maintenance of stemness [138] [139]; in the formation of mammosphere in 
breast cancer [138]; and it was found to be expressed in proliferating cells [146]. 
The western blot displayed in Figure 4.4 showed that the expression of DEK was 
upregulated in TNBC cell lines. However, its expression was also observed across 
the Luminal cell lines. One explanation could be that it is important for cell 
maintenance, given that its normal cellular functions include the regulation of 
transcription, the splicing of mRNA and the replication and repair of DNA [128] 
[129] [130].  
The expression of SSRP1 was also found to be upregulated in TNBC cell lines. The 
western blot shown in Figure 4.4 B also shows that there was strong expression in 
some Luminal cell lines. This could be because SSRP1 plays a general role as a 
chromatin-associated protein, forming a FACT complex with subunit FACT 
complex subunit SPT16 (SUPT16) [131]. It is also involved in: DNA replication 
and repair [147] [148], the disassociation of histone proteins to regulate gene 
transcription [140], and as a transcriptional co-activator for p63 [132]. It has also 
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been found to promote cell proliferation, and transform and maintain cell stemness 
in breast cancer [142] [143].  
Lastly, the expression of PSIP1 was determined. It was found to be upregulated in 
the TNBC cell lines. However, as with SSRP1, there were also PSIP1 expressions 
in some Luminal cell lines. This could be because it plays an important role in 
general cell function. PSIP1 was originally identified as taking part in the regulation 
of transcription in lens epithelial cells [134]. It also acts as a transcription co-
activator [135], as a promoter of cell proliferation [134] and as a repairer of DNA 
double-strand breaks [149]. These general roles are important for cell survival and 
could explain its expression in both TNBC and Luminal subtypes. Furthermore, it 
is known that PSIP1 regulates the expression of genes in the cell cycle, and 
promotes migration and invasion in breast cancer [144]. Table 4.11 summarises the 
known functions of DEK, SSRP1 and PSIP1 in breast cancer.  
4.3.2 Evaluation of the binding of candidates in TNBC cell lines 
Antibodies specific to DEK, SSRP1 and PSIP1 were used in ChIP studies to 
determine whether they were true proteins that bound to Sites A and B on BCL11A 
in MDA-MB-231 cells. The experiments showed that all of their bindings were 
enriched at both target sites, with some being statistically significant. Next, their 
binding specificities to these sites were evaluated through the use of primers which 
amplified regions that flanked Sites A and B. These primers were designed to be as 
close to the targets as possible, and thus it was not surprising to find enrichment in 
these regions as well. 
The findings were also confirmed in another independent cell line, HCC1569. This 
cell line was shown through the use of western blots to exhibit stronger expressions 
of DEK, SSRP1 and PSIP1 than in MDA-MB-231 cells. The results are shown in 
Figure 4.4. The ChIP data gathered from this cell line led to a similar conclusion to 
that drawn from the work with MDA-MB-231 cells, which was that DEK, SSRP1 
and PSIP1 bindings were enriched at Sites A and B, some of which enrichment was 
again statistically significant. As described earlier, the specificities of their bindings 
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were also assessed using primers specific to nearby regions. The bindings of all 
three proteins were enriched at the nearby sites.  
In summary, the results for these two TNBC cell lines show that the bindings of 
DEK, SSRP1 and PSIP1 were enriched at the target sites and at their neighbouring 
regions. 
We also wanted to assess whether DEK, SSRP1 and PSIP1 showed binding bias 
towards particular sites, and this was accomplished by way of statistical analysis on 
the ChIP results. We can conclude that this potential binding bias depends on the 
cell lines tested. For instance, DEK binding did not display statistically significant 
differences when comparing primers against each other in HCC1569, while the 
same cannot be said for MDA-MB-231 cells. The results also suggest that SSRP1 
showed binding bias towards the sites studied in MDA-MB-231 cells, but this bias 
was shown towards only two of these sites in HCC1569. PSIP1 bindings were found 
to show no statistically significant binding bias in either cell line.  
To summarise, DEK bindings were enriched at Sites A and B in both cell lines but 
the bias of its binding towards specific sites was inconclusive. One reason could be 
that the sample size used in the experiment was too small for post-hoc tests to detect 
robust statistical significance in observed differences. SSRP1 bindings were also 
enriched at the target sites and statistical analysis showed some bias towards 
particular binding sites. Finally, PSIP1 bindings were found to be enriched at both 
target sites without any bias.  
4.3.3 Do DEK, SSRP1 and PSIP1 form a complex? 
Analysis of the Search Tool for the Retrieval of Interacting Genes (STRING) 
database has suggested that these three proteins might interact together, with DEK 
as a central protein in human cells. However, no recognised interactions with 
BCL11A were found. This STRING database is an online resource with known and 
predicted protein-protein interactions sourced from experimental data and 
computational assessments [150].  
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Co-immunoprecipitation experiments were performed to investigate whether true 
interactions were present. Magnetic beads were incubated with DEK antibody and 
attempts were made to pull-down SSRP1 and PSIP1 from MDA-MB-231 cells. 
Initial attempts with this cell line proved to be technically difficult. To overcome 
this, the experiments were performed in HCC1569 cells. This was due to the greater 
expression of DEK, SSRP1 and PSIP1 in this cell line in comparison with MDA-
MB-231 cells. However, due to time constraints, the protocol was not optimised. 
Matysiak’s study has previously shown that SSRP1 interacts with the PSIP1 p75 
isoform to regulate HIV-1 integration [151]. Therefore, investigation of a possible 
similar interaction in TNBC would be worthwhile. Co-IP experiments will be 
followed up in the future.  
In conclusion, DEK, SSRP1 and PSIP1 were identified through the RIME analysis 
to be putative regulators of BCL11A. Their bindings and ability to form a complex 
were also investigated. Chapter 5 will describe their functions and impact on the 
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5.1 Introduction 
DEK, SSRP1 and PSIP1 were identified through the analysis of the RIME 
proteomics, as discussed in Chapter 4. These factors have known roles in breast 
cancer, which are summarised in Table 4.11.  
Apart from the roles already identified that DEK plays in breast cancer, one study 
has shown that translation of DEK is dependent on transfer RNA (tRNA) post-
transcriptional modifying enzymes, elongator complex protein 3 (ELP3) and 
thiouridylase proteins 1/2 (CTU1/2). It has also shown that DEK facilitates the 
internal ribosome entry site-dependent (IRES-dependent) translation of lymphoid-
enhancer binding factor 1 (LEF1) to promote breast cancer invasion and metastasis 
[152]. This suggests that DEK may have a role at both transcription and translation 
level in breast cancer.  
On the other hand, the complex that facilitates chromatin transcription, or the FACT 
complex, in which SSRP1 is a subunit, has been found to bind to DNA and block 
replication or repair during cisplatin treatment in non-small-cell lung cancer. 
Hence, SSRP1 plays a part in an important mechanism which facilitates cisplatin-
induced apoptosis [153].  
To investigate the effects of DEK, SSRP1 and PSIP1, and in particular their impact 
on the expression of BCL11A in TNBC, expression of these proteins was knocked 
down using short hairpin RNA (shRNA). These shRNA molecules bind to their 
target mRNA transcript through complementary base pairing, which leads to 
degradation and thus a reduction in expression [112].  
The aim of the work described in this chapter is to investigate the effects of DEK, 
SSRP1 and PSIP1 through the knocking-down of their expressions with shRNA to 
determine whether these proteins participate in the regulation of the expression of 
BCL11A in TNBC.  
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5.2 Results 
5.2.1 The design of primers for the shRNA-expression plasmid 
In order to knock-down the expression of DEK, SSRP1 and PSIP1, sequences of 
shRNA primers were first designed and obtained from the MISSIONâ Sigma 
database. This database contains verified shRNA sequences that target specific 
regions of the mRNA transcript, and users can design shRNA primers for their 
genes of interest [118]. These sequences along with their complementary sequences 
were then blasted against the human genes for DEK, SSRP1 and PSIP1 from the 
UCSC genome browser to verify their specificities regarding target regions. The 
position of the targets covered through the use of these shRNA primers are shown 
in Figure 5.1 A. Scrambled shRNA, which does not target any known human or 
mouse genes, was used as a control in the following experiments.  
5.2.2 The generation of stable cell lines that express shRNA 
After the sequences were obtained and verified, these shRNA primers were cloned 
into the expression plasmid that expresses a geneticin-resistance gene and EGFP 
fluorescence signals. The features of the shRNA-expression plasmid are shown in 
Figure 5.1 A.  
The shRNA-expression plasmids were then transfected into MDA-MB-231 cells. 
The geneticin-resistance gene enabled the selection of transfected cells and 
generation of a stable cell line by FACS for EGFP-positive cells. The schematic of 
this experimental design is shown in Figure 5.1 B. In addition to these selection 
markers, the plasmid also adopts the PB transposon system through a cut-and-paste 
mechanism, as described in Chapter 3. After the establishment of cell lines which 
constitutively expressed these shRNA plasmids, the degree of knock-down of their 
target genes would be determined and their functional effect investigated. 
5.2.3 The validation of shRNA knock-down 
The first validation performed after the transfection of these primers into MDA- 




Figure 5.1: The design of shRNA primers and the schematic of the 
experimental plan. 
(A) shRNA primers for DEK, SSRP1 and PSIP1 were first obtained from 
MISSION, Sigma, and blasted against the corresponding genes taken from the 
UCSC genome browser. The red boxes show the positions of shRNA targeting on 
each gene. There were two targets for DEK and PSIP1, and one for SSRP1. Next, 
these primers were cloned into the shRNA-expression plasmid with the selection 
markers EGFP and the geneticin-resistance gene through an adaptation of the PB 
transposon system. (B) shows the schematic for the generation of stable cell lines. 
The shRNA-expressing plasmids were transfected into MDA-MB-231 cells, 
followed by geneticin selection and FACS. Transfected cells were collected after 
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MB-231 cells was to determine whether the expressions of their targets, DEK, 
SSRP1 and PSIP1, were knocked down by shRNA. Transfected cells were 
collected, RNA extracted, and expression investigated using qPCR. One primer per 
gene was used in the qPCR step and the expressions were plotted on a graph in 
relation to the fold change of the control shRNA (CSH). The CSH plasmid 
contained scrambled shRNA as mentioned in section 5.2.1.  
The position of the primer used to detect DEK expression is shown in Figure 5.2 A 
and qPCR data are listed in 5.2 B. The result showed successful knock-down of 
DEK expression in both shRNAs, and more knock-down was achieved when 
shRNA 1 was used.  
The expression of SSRP1 was studied in the same way. One primer was chosen; its 
position is shown in Figure 5.3 A. The qPCR plot displayed in Figure 5.3 B showed 
that the expression of SSRP1 was knocked down by more than half in comparison 
with the CSH sample.  
Lastly, qPCR was performed to quantify the expression of PSIP1. The position of 
primer used is shown in Figure 5.4 A. The data displayed in Figure 5.4 B showed 
successful knock-down when treated with both shRNAs, although shRNA 1 was 
shown to be more efficient at knock-down than shRNA 2.  
The knock-down of factors through the use of shRNA was also investigated at a 
protein level by collecting protein lysates and performing western blots, as shown 
in Figure 5.5. CSH was used as a control and tubulin as a loading control. It can be 
seen that the knock-down of DEK expression was reflected at the protein level. 
However, SSRP1 knock-down was not reflected when SSRP1 shRNA 1 plasmid 
was employed, as seen in the western blot. The antibody used to perform this 
western blot detected both isoforms of PSIP1, p75 and p52. The shRNA 1 sample 
was seen to contain less p75 isoform than the CSH and shRNA 2 samples. However, 
no difference was observed in the quantity of p52 isoform between the PSIP1 
shRNAs and CSH.  
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Figure 5.2: Validation of the expression of DEK gene knock-down with RT-
qPCR.  
(A) shows the positions on DEK of primer 1 used in the qPCR step. The blue boxes 
represent the exons. (B) shows the graph of DEK gene knock-down, plotted in 
relation to the fold change to CSH control. DEK expression was knocked-down in 
the DEK shRNA 1 sample to a greater degree than in the DEK shRNA 2 sample. 
(* <0.05, One-way Anova, Dunnett post-hoc test, n=2 (Average value of two sets 
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Figure 5.3: Validation of the expression of SSRP1 gene knock-down with RT-
qPCR.  
(A) shows the positions of primer 1 on the SSRP1 gene used in the qPCR step. The 
purple boxes represent the exons. (B) shows the graphs of SSRP1 knock-down, 
plotted in relation to the fold change to CSH control. SSRP1 expression was 
knocked-down in the SSRP1 shRNA 1 sample. (* <0.05, t-test, n=2 (Average value 
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Figure 5.4: Validation of the expression of the PSIP1 gene knock-down with 
RT-qPCR.  
(A) shows the positions of primer 1 on PSIP1 used in the qPCR step. The orange 
boxes represent the exons. (B) shows the graphs of PSIP1 knock-down, plotted in 
relation to the fold change to CSH control. PSIP1 expression was knocked-down 
in both PSIP1 shRNA 1 and shRNA 2 samples but to a greater extent in the shRNA 
1 sample. (* <0.05, One-way Anova, Dunnett post-hoc test, n=2 (Average value of 
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Figure 5.5: Protein expression of DEK, SSRP1 and PSIP1in shRNA samples.  
Proteins from shRNA samples were collected and western blots were performed. 
CSH was used as a control and tubulin as a loading control. The red boxes show 
the results for samples that correspond with the antibody used. No change in SSRP1 
expression was observed in the SSRP1 shRNA-1 sample. The antibody used for 
detecting PSIP1 detected both isoforms. More PSIP1 p75 was expressed in the 
PSIP1 shRNA 1 sample than in the shRNA 2 sample, while expression of the p52 
isoform was unchanged across the samples. For DEK, more expression was 
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5.2.4 Exploration of the effects of shRNA knock-down 
5.2.4.1 The effects of shRNA knock-down on expression of BCL11A  
After the validation of the efficiencies of knock-down of the expressions of DEK, 
SSRP1 and PSIP1 with shRNAs, their effects on the expression of BCL11A were 
investigated. The qPCR result obtained is shown in Figure 5.6 A. No effect on 
expression of BCL11A was seen when DEK, SSRP1 or PSIP1 were knocked down 
individually. The y-axis of the graph was plotted in relation to the quantity of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and in relation to fold 
change of CSH. GADPH was used as an internal control as it is constitutively 
expressed in most cells and tissues. The knock-down of the expression of PSIP1 
with both shRNA 1 and shRNA 2 resulted in the least expression of BCL11A 
among the shRNA samples. This is shown in the western blot displayed in Figure 
5.6 B. Tubulin was used as loading control.  
In addition to using the GAPDH gene as a control, the gene protein phosphatase 2 
regulatory subunit B delta (PPP2R2D) was also used. PPP2R2D is responsible for 
the regulation of the cell cycle at the mitosis check-points [154] and was used as a 
housekeeping gene in the qPCR experiment. Housekeeping genes are important to 
maintain the basic cell functions for survival regardless of their roles [155]. 
Moreover, the primers of PPP2R2D were readily available from other work 
performed in our group. The qPCR result for this experiment is shown in Figure 
5.7. No differences were observed across the shRNA samples tested.  
5.2.4.2 The functional effects of shRNA knock-down 
Apart from determining the effect of shRNA knock-down on the expression of 
BCL11A, the investigation was extended to study functional effects. Proliferation 
assay was performed first. This assay involved the seeding of 200 cells per sample 
and the calculation of the cell number every two days across 16 days. The result is 
shown in Figure 5.8A. The log of the cell number has been plotted against the 
number of days for easy visualisation and interpretation. No difference was seen in 
cell proliferation from the shRNA samples across the 16 days tested.  
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Figure 5.6: Evaluation of the effects of shRNA knock-down on expression of 
BCL11A.  
The RT-qPCR graph in (A) reveals that there is no change in expression of BCL11A 
across the samples. (B) shows a western blot which indicates that knock-down of 
PSIP1 expression did affect protein expression of BCL11A. Tubulin was used as a 
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Figure 5.7: Evaluation of the effects of shRNA knock-down on global gene 
expressions. 
Primers for PPP2R2D were used in the RT-qPCR. No effects on gene expression 
as a whole were observed after knock-down of DEK, SSRP1 or PSIP1 with shRNA. 
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The knock-down of the expressions of DEK, SSRP1 and PSIP1 with shRNA on the 
effect of the potential to form colonies was also investigated. One hundred cells 
were seeded in the Matrigel and the numbers of colonies were counted after 14 
days. As with the proliferation assay, it was observed in Figure 5.8 B that shRNA 
knock-down did not affect colony formation.  
In summary, the knock-down of DEK, SSRP1 and PSIP1 did not affect the 
expression of BCL11A or influence the rate of cell proliferation or the potential to 
form colonies. One explanation for these results is that the three proteins do not 
work individually and that a combination of the three would be needed to regulate 
the expression of BCL11A or show functional effects. This hypothesis was tested 
by knocking-down the three proteins in combination.  
5.2.5 Candidates work together to regulate expression of BCL11A  
The schematic of the experimental plan to investigate the effect of the combination 
of the three proteins on expression of BCL11A is shown in Figure 5.9. The plan was 
similar to that used to knock-down the expressions when one shRNA was used per 
cell line. MDA-MB-231 cells were co-transfected with the shRNAs for DEK, 
SSRP1 and PSIP1. It was established in section 5.2.3 that the DEK shRNA 1 
showed greater efficiency in knocking-down the expression of its target and PSIP1 
shRNA 1 similarly was more efficient at knocking-down expression of PSIP1. The 
SSRP1 shRNA 1 plasmid was used in addition to the two mentioned. Transfected 
cells were selected using Feneticin and FACS to generate a stable cell line. The 
knock-down of the targets was then confirmed through the use of qPCR.  
Firstly, the quantity of knock-down of expression of DEK was determined through 
the use of a pair of primers during the qPCR step. The positions of these primers 
pairs are shown in as previously in Figure 5.2. DEK expression was knocked-down 
in samples co-transfected with SSRP1 sh1 and PSIP1shRNA 1, but a greater degree 
was observed in the cells containing SSRP1 shRNA are shown in Figure 5.10. Cells 
co-transfected with DEK shRNA 1 and SSRP1 shRNA 1 or PSIP1 shRNA 1 were 
collected and the RNA was extracted. The qPCR result displayed in Figure 5.10 B 
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Figure 5.8: Functional studies of the knock-down of DEK, SSRP1 and PSIP1.  
The proliferation assay after 16 days is plotted as the log of cell number in (A). No 
difference in the rate of proliferation was observed among the shRNA samples, as 
shown in (B). n=3 
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show that expression of DEK has been successfully knocked-down in both samples. 
Secondly, we determined the knock-down of SSRP1 in cells co-transfected with 
SSRP1 shRNA 1 and DEK shRNA 1 or PSIP1 shRNA 1. The cells were collected 
and RNA extracted. The positions of the primers used in the qPCR experiment are 
shown in Figure 5.11 A and the results in 5.11 B. The expression of SSRP1 was 
found to be knocked down by the SSRP1 shRNA 1 plasmid in both cell lines. 
Lastly, cells co-transfected with PSIP1 shRNA 1 and DEK shRNA 1 or SSRP1 
shRNA 1 were collected to determine the expression of PSIP1. Again, the positions 
of the primers used in the qPCR step is shown in Figure 5.12 A. Cells co-transfected 
with PSIP1 shRNA 1 and DEK shRNA 1 or SSRP1 shRNA 1 plasmids were found 
to contain knocked-down PSIP1 expression in Figure 5.12 B. A greater degree of 
knock-down was observed in samples co-transfected with PSIP1 shRNA 1 and 
DEK shRNA 1.  
Protein lysate in the cells co-transfected with two shRNA plasmids were collected 
and western blot was performed. The result in Figure 5.13 showed that the knock-
down of DEK in samples co-transfected with DEK shRNA 1 and SSRP1 shRNA 1 
or PSIP1 shRNA 1 was reflected at the protein level. Similarly, SSRP1 knock-down 
was seen in cells co-transfected with SSRP1 shRNA 1 and DEK shRNA 1 or PSIP1 
1 and DEK shRNA 1. For PSIP1, no change was observed in the levels of the PSIP1 
p75 isoform across the samples, but the p52 isoform was only observed in samples 
co-transfected with PSIP1 shRNA 1 and SSRP1 shRNA 1.  
 
5.2.5.1 Double shRNA knock-down affects expression of BCL11A 
The effect on the expression of BCL11A of the co-transfection of three cell lines 
with two shRNA plasmids was compared with CSH and the results are shown in 
Figure 5.14 A. Knock-down of multiple genes resulted in a greater than 60 per cent 
reduction in the expression of BCL11A in all the cell lines tested. Among them, 
double knock-down with SSRP1 shRNA 1 and PSIP1 shRNA 1 plasmids showed 
the greatest reduction in expression of BCL11A. To determine whether this knock-
down would show a global effect, we used PPP2R2D as a control. The results in  




Figure 5.10: Validation through RT-qPCR of the knock-down of expression of 
DEK in double knock-down samples. . 
(A) is a graphical representation of the positions of primers on DEK used in qPCR.. 
The blue boxes represent the exons. DEK expression was knocked-down in both 
samples as shown in (B) and (C) but to a greater extent in the DEK shRNA 1/SSRP1 
shRNA 1 sample. (*<0.05, One way Anova, Dunnett post-hoc test, n=2 (Average 
value of two sets each performed in triplicate)) 
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Figure 5.11: Validation through RT-qPCR of the knock-down of expression of 
SSRP1 in double knock-down samples. 
(A) is a graphical representation of the positions of primers on SSRP1 used in qPCR. 
The purple boxes represent the exons. SSRP1 expression was knocked-down in both 
samples shown in (B) and (C) but to a greater extent in cells co-transfected with 
DEK shRNA 1/SSRP1 shRNA 1. (*<0.05, One way Anova, Dunnett post-hoc test, 
n=2 (Average value of two sets each performed in triplicate)) 
* 
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Figure 5.12: Validation through RT-qPCR of the knock-down of expression of 
PSIP1 in double knock-down samples. 
(A) is a graphical representation of the positions of primers on PSIP1 used in qPCR. 
The orange boxes represent the exons. PSIP1 expression was knocked-down in the 
DEK shRNA 1/PSIP1 shRNA 1 sample using both primers, but only with primer 2 
in cells co-transfected with SSRP1 shRNA 1/PSIP1 shRNA 1. (*<0.05, One-way 
Anova, Dunnett post-hoc test, n=2 (Average value of two sets each performed in 
triplicate)) 
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Figure 5.13: Protein expression for DEK, SSRP1 and PSIP1 in double knock-
down samples.  
Lysates of proteins produced in double knock-down samples were collected and 
western blot was performed. CSH was used as a control and tubulin as a loading 
control. The red boxes show samples that correspond with the antibody used. 
SSRP1 expression was knocked-down in cells co-transfected with DEK shRNA 1 
or PSIP1 shRNA 1. A greater degree of SSRP1 knock-down was observed in cells 
with DEK shRNA 1 and SSRP1 shRNA 1. No change was observed in the PSIP1 
p75 isoforms among the double knock-down samples, but the PSIP1 p52 isoform 
was only seen in the sample co-transfected with SSRP1 shRNA 1 and PSIP1 
shRNA 1. Knock-down of DEK was performed in samples co-transfected with 
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Figure 5.14 B show that double knock-down with DEK shRNA 1 and SSRP1 
shRNA 1 or PSIP1 shRNA 1 had a global effect on gene expression, while this 
effect was absent when SSRP1 and PSIP1 were knocked-down together.  
Protein lysates were collected from these cell lines to investigate whether these 
knock-down effects were translated to the protein level. The western blot in Figure 
5.15 shows that expression of BCL11A was not seen at the protein level in any of 
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Figure 5.15: Protein expression for BCL11A in double knock-down samples. 
Lysates of proteins produced in double knock-down samples were collected and 
western blot performed. CSH was used as a control and tubulin as a loading control. 
BCL11A expression was knocked-down in cells co-transfected with DEK shRNA 
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5.3 Discussion 
5.3.1 Evaluation of the experimental design 
To understand the ways in which DEK, SSRP1 and PSIP1 could regulate the 
expression of BCL11A, we obtained shRNA primers from the MISSIONâ Sigma 
database and determined their specificities for our genes of interest by blasting them 
against the data contained in the UCSC genome browser. The results produced 
confidence that these primers targeted DEK, SSRP1 or PSIP1. They were then 
cloned into the shRNA-expressing plasmid together with primers that contained 
complementary sequences. Two shRNAs for DEK and PSIP1 each were cloned 
successfully while one was cloned for SSRP1. Next, these plasmids were 
transfected into MDA-MB-231 cells using the PB transposon system, as described 
in Chapter 3. The selection markers, EGFP and the geneticin-resistance gene, in the 
shRNA-expression plasmid enabled selection of transfected cells.  
After generating stable cell lines which constitutively expressed the shRNA for the 
targets, cells were collected, RNA extracted and qPCR performed to determine 
whether the designated genes had been knocked down. The strategy employed to 
determine the degree of knock-down was use of one specific primer per gene during 
the qPCR step. The results shown in Figures 5.2- 5.4 demonstrate that the 
expressions of DEK, SSRP1 and PSIP1 have been knocked down by their 
corresponding shRNAs. Moreover, it was observed from the transfected cell lines 
that the DEK shRNA 1, SSRP1 shRNA 1 and PSIP1 shRNA 1 plasmids were more 
effective at knocking-down their target genes in comparison with the other designed 
shRNAs. The knock-down of DEK and SSRP1 in cells were both reflected at the 
protein level. This could be due to the positions of the target regions on DEK and 
SSRP1 and their potential to influence the stability of the protein or protein folding.  
5.3.2 Functional effects of shRNAs 
Following the validation of the methods of knock-down employed for expression 
of mRNA, functional assays were set up to study the effects. The choice of function 
studies was determined by the known functions of DEK, SSRP1 and PSIP1 in breast 
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cancer. Firstly, the effects on expression of BCL11A were investigated, as the aim 
of this project was to identify potential regulators that might influence the 
expression of BCL11A. Moreover, DEK and PSIP1 proteins are known to regulate 
transcription [129] [135] [156] [157], while SSRP1 is known to facilitate 
transcription by disassociating the histone proteins and is known to act as a subunit 
for the FACT complex [131]. This complex is also important for regulating 
transcription.  
The qPCR results displayed in Figures 5.6 show that knocking down the three 
proteins did not affect the expression of BCL11A at the RNA level. These results 
also translate at the protein level, except in the case of cells transfected with PSIP1 
shRNA. The knock-down of the expression of PSIP1 has been shown to have 
resulted in the reduction of protein expression by BCL11A. This suggests that PSIP1 
might be important in the expression of BCL11A.  
GAPDH was used as an internal control for experiments in which we have 
determined the effect of knocking down the three proteins on expression of 
BCL11A. In addition, PPP2R2D was chosen as a second control. PPP2R2D was 
used due to its function as a housekeeping gene whose expression did not vary in 
tissues and cells and which was responsible for the regulation of the cell cycle at 
the mitosis check-points [154]. It can be seen from the results shown in Figure 5.7 
that knocking down the expressions of DEK, SSRP1 and PSIP1 did not affect the 
expression of PPP2R2D. This suggests that these proteins may regulate gene 
expression selectively and do not affect other genes on a global scale.  
Proliferation and colony assays were also performed. It is known that DEK, SSRP1 
and PSIP1 perform functions in breast cancer, including the formation of 
mammosphere [138] and involvement in transformation [142] [143] and migration 
[138] [139] [144] . Other functions were summarised in the discussion section of 
Chapter 4. This work has shown that knocking down the three genes did not affect 
the rate of cell proliferation or the cells’ ability to form colonies. These results 
suggest that these proteins may show selectivity in their functions in different breast 
cancer subtypes. Another potential explanation is that DEK, SSRP1 and PSIP1 do 
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not act alone. To investigate this hypothesis, we co-transfected various 
combinations of shRNAs to target two different mRNA transcripts at the same time.   
5.3.3 The effect of double shRNA knock-down 
As in single shRNA transfection experiments, cells with two shRNAs were co-
transfected, then selected through geneticin and FACS sorting. Cells from the stable 
cell lines were collected, RNA extracted and qPCR performed to determine the 
degree of gene knock-down.  
We will first discuss the results of knocking-down in cells with two shRNAs. 
Firstly, cells co-transfected with DEK shRNA. DEK was knocked-down at both 
RNA and protein levels in cells that had been co-transfected with SSRP1 sh1 or 
PSIP1 sh1 plasmids. Among these samples, cells co-transfected with SSRP1 
shRNA 1 showed the greatest level of knock-down in comparison with cells 
transfected with DEK shRNA alone. Secondly, similar result was observed that a 
greater level of SSRP1 was knocked-down in cells co-transfected SSRP1 shRNA 1 
with DEK shRNA 1 than PSIP1 shRNA 1. Lastly, the same was seen in the samples 
co-transfected PSIP1 shRNA 1 with DEK shRNA 1. We have observed the same 
trend in these results, which is a greater level of knock-down when cells were co-
transfected with DEK shRNA 1.  
After the evaluation of the degree of knock-down in the expression of the targets 
by their corresponding shRNAs, we have also investigated the impact of shRNAs 
on expression of BCL11A. It was surprising to find that through the combination of 
knock-down of two genes at the same time, a great reduction in the expression of 
BCL11A was observed at both RNA and protein levels. All three double knock-
down cell lines showed a reduction of over 60 percent in the expression of BCL11A 
in comparison with the CSH sample. Among them, the greatest effect on BCL11A 
expression was observed in the experiments in which SSRP1 and PSIP1 were 
knocked-down. In addition, we have shown through the PPP2R2D qPCR results 
that a global effect is not observed in this cell line. These results suggest that SSRP1 
and PSIP1 may work together and are more selective in the regulation of expression 
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of BCL11A than are other genes, in comparison with other double knock-down 
combinations. In addition,  a common trend was also noticed in the PPP2R2D 
qPCR results– cells co-transfected with DEK shRNA 1 will result in a global effect 
on gene expressions. These results suggest that DEK might influence global gene 
expression including SSRP1 and PSIP1. 
5.3.4 Proposed mechanism for regulation of expression of BCL11A by DEK, 
SSRP1 and PSIP1 
A combination of these results with known literature leads to a proposed 
mechanism of ways in which DEK, SSRP1 and PSIP1 may regulate the expression 
of BCL11A. In the single shRNA knock-down experiments, the knock-down of 
DEK did not have any effect on expression of BCL11A. However, knock-down in 
combination with SSRP1 and PSIP1 significantly reduced expression of BCL11A 
at both gene and protein levels. This can be explained by consideration of the known 
functions of SSRP1 and PSIP1 as transcription co-activators. Therefore, they might 
recruit DEK to regulate transcription. In addition, the qPCR result in PPP2R2D, 
shown in Figure 5.14, suggests that knock-down of DEK affects general gene 
expressions rather than those BCL11A specifically. These results suggest that DEK 
is a general regulator for transcription, and this matches its known functions. 
Secondly, the knock-down of SSRP1 alone had no effect on BCL11A’s gene or 
protein expressions. However, a combination of shRNA knock-down of SSRP1 
with knock-down of DEK or PSIP1 significantly reduced both gene and protein 
expression of BCL11A. These results suggest that SSRP1 requires the presence of 
additional proteins to regulate transcription of BCL11A and may act as a 
transcriptional co-activator. The proposed mechanism is shown in Figure 5.16 A.  
Lastly, single shRNA knock-down of PSIP1 had no effect on gene expression by 
BCL11A but produced a partial reduction at the protein level. On the other hand, 
combination knock-down of PSIP1 with DEK or SSRP1 led to a significant 
reduction in both BCL11A’s gene and protein expressions. These results led to the 
proposal, shown in Figure 5.16 B, that PSIP1 may act in a similar way to SSRP1 as 
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a transcriptional co-activator but through the recruitment of different transcription 
factors. PSIP1 also regulates protein expression of BCL11A.  
In addition, the knock-down of PSIP1 and SSRP1 together had no effect on global 
gene expression, in contrast with the combination knock-down of DEK with SSRP1 
or PSIP1. It is also worth noting that the knock-down of SSRP1 alone affected 
general gene expression, i.e. these cells do not express SSRP1 but still express 
PSIP1. These results indicate that PSIP1 may negatively regulate global gene 
expressions, and its presence in a mixture may negatively regulate the recruitment 
of SSRP1 and other associated factors. 
5.4 Conclusion 
To conclude, this chapter details the establishment of cell lines that contain one or 
two types of shRNA molecules that target DEK, SSRP1 or PSIP1. The knock-down 
of these proteins individually does not affect the expression of BCL11A, nor does it 
affect the functional assays. However, we have shown that combinations of either 
two of these proteins are needed to regulate gene expression. Among them, SSRP1 
and PSIP1 might work together to play a bigger role as regulators of BCL11A, in 
comparison with mixtures of DEK with SSRP1 or with PSIP1. These results imply 
that DEK, SSRP1 and PSIP1 could be potential targets in the development of novel 
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Figure 5.16: Proposed mechanisms of regulation of BCL11A’s expression.  
(A) shows the proposed mechanism of action by SSRP1, which acts as a co-
transcriptional factor to recruit other transcription factors to regulate the expression 
of BCL11A. (B) shows the speculated mechanism of action for PSIP1. It indicates 
a number of different roles. Firstly, it acts as a transcriptional co-activator that 
recruits different transcription factors to those recruited by SSRP1. Secondly, it 
takes part in the regulation of protein expression by BCL11A. Finally, it negatively 
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6.1 Discussion 
6.1.1 Rationale behind the research aim and Achievements 
The main aim of this study is to investigate the transcriptional regulation of BCL11A 
in Triple-negative breast cancer. The chief reason for conducting this project comes 
from the clinical challenges in treating this breast cancer subtype. Clinical 
characteristics of TNBC include high mortality rates and recurrence within 5 years 
[42] in comparison to other subtypes. The lack of hormonal and HER-2 growth 
factor receptors means that conventional therapies are unsuitable for treating TNBC 
patients and chemotherapy is the only treatment available. These call for the 
identification of new molecular markers and drug treatments for TNBC patients. 
Advancement on TNBC’s research has led to the identification of BCL11A as an 
oncogene and our group has demonstrated its role in initiating and maintaining 
tumourigenesis [74]. BCL11A is known to be involved in many biological 
functions. In the immune system, it silences g-globin chains and participates in the 
complex that governs globin chain switching during development [62] [64] [65] 
[66] and regulates the development of T- and B-cells [63]. It is also responsible for 
regulating axon branching and dendrite growth [119] in the neural system. Its 
importance in these biological systems means that developing an inhibitor against 
BCL11A directly was unfavourable and the identification of potential regulatory 
factors in this project would shed light on drug development for TNBC patients 
against this oncogene.  
I utilise the CRISPR-Cas9 system coupled with RIME proteomics to investigate 
potential factors regulating BCL11A’s expression in this project. The importance of 
the sites I chose to study was evaluated in Chapter 3; namely, I have identified 
DEK, SSRP1, and PSIP1 as potential putative regulators of BCL11A from RIME 
proteomics in Chapter 4, and I then demonstrated that SSRP1 and PSIP1 work in 
concert to regulate BCL11A in TNBC using a RNA interfering technique in Chapter 
5.  
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The specific use of the CRISPR-Cas9 system in my project is novel in two key 
aspects, compared to conventional implementation. Firstly, dCas9 is used instead 
of normal Cas9, and repurposed to enable targeting of specific sites of BCL11A 
while avoiding DNA double-strand breaks that would otherwise be introduced. 
Secondly, rather than using dCas9 as an enzyme, I use dCas9 as a protein tag that 
is pulled down by specific antibodies. This allows us to identify and study DEK, 
SSRP1, and PSIP1 as regulators for BCL11A’s expression in TNBC at our sites of 
interest. 
6.1.2 Evaluating the CRISPR-Cas9 system 
The CRISPR-Cas9 system is used to study transcriptional regulations at specific 
BCL11A’s sites. This system was originally identified as a defense mechanism 
against foreign DNA by bacteria and archea using a RNA-guided DNA recognition 
system [89] [90]. This was achieved by transcribing foreign DNA from the host’s 
genome incorporated during the last encounter. This transcript, called crRNA, 
recognises complementary sequences from invaders upon a second encounter, 
guides Cas9 to the site and induces DNA double-strand breaks [95]. Section 1.6.1.1 
described the detailed mechanism. Since its discovery, the CRISPR-Cas9 system 
has been adapted for genetic engineering and genome editing [103] [104] [105] 
[106] [109] [110].  
Taking advantage of the strengths of this system, I designed gRNA, which acts in 
the same capacity as crRNA in bacterial defence systems, to target specific BCL11A 
sites (Sites A and B) in my project. These target sites are selected from the UCSC 
genome browser as active transcription sites through display of the H3K27Ac 
histone marker and hypersensitivity to DNaseI. I validated this using a normal Cas9 
to delete these target sites. Deletion of entire Sites A and B was initially attempted 
but cells did not survive during selection. Therefore, I switched to deleting smaller 
fragments within these sites. This could have allowed me to identify smaller sites 
within Sites A and B that regulate the expression of BCL11A. Results in Figure 3.2 
suggest that Sites A and B, while important for BCL11A’s expression,  also affects 
downstream pathways and deleting them entirely was thus detrimental to cell 
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survival. This could be further investigated with functional assays, for example a 
survival assay. 
Apart from using normal Cas9, I also employ dCas9 to target BCL11A sites instead 
of inducing DNA double-strand breaks and use this protein as a tag for pulling down 
itself along with proteins in close proximity for the RIME experiment. This dCas9 
is expressed with an EGFP fluorescence signal through a self-cleavable 2A protein. 
In addition, I use the Tet-On system to induce these proteins. Data from Figure 3.5 
show successful induction of dCas9 using Tetracycline derivative, Doxycycline, 
and illustrate how the EGFP level correlates with expression of the dCas9 protein. 
One disadvantage of the CRISPR-Cas9 system is the possibility of CRISPR 
interference— the blockage of genetic regions and accessibility of proteins by Cas9 
[110]. This is particularly relevant to my project as the chief aim is precisely to 
study transcription regulation. To evaluate this effect, I perform a timed induction 
experiment by collecting RNA at various time-points within 24 and 48 hours of 
Doxycycline induction. Results in Figure 3.5 show that dCas9 induction does not 
affect the expression of BCL11A regardless of the time of induction. I also evaluate 
the specificity of dCas9 by performing ChIP experiments using specific Anti-V5 
antibodies against the multi-tagged dCas9. Results in Figures 3.6 and 3.7 show 
binding specificities at both Sites A and B. In the future, ChIP-sequencing 
experiments should be considered to evaluate the global binding of dCas9 on the 
human genome. This data will provide valuable insights on the binding and off-
target effects on a global scale.  
In order to identify transcriptional regulators which are upregulated or have specific 
expressions in TNBC, I attempted to perform this CRISPR-Cas9 system on 
Luminal cell lines MCF7 and T47D. Unfortunately, there was little success with 
transfection and establishment of stable cell lines proved to be challenging.  
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6.1.3 Evaluating the experimental design and proteomic analysis from the 
RIME experiment 
I discussed in Chapter 4 that DEK, SSRP1, and PSIP1 are identified from the RIME 
analysis. RIME is a technique developed to study unknown proteins, in the context 
of this project those which regulate transcription of BCL11A. It couples ChIP which 
pulls down dCas9 as well as proteins sitting in close proximity, with mass 
spectrometry which identifies these proteins. This technique also allows the study 
of endogenous proteins in their native state through the fixation of stable cell lines 
established in Chapter 3 with formaldehyde, conserving even transient interactions 
[83]. The nuclei are then isolated in an attempt to identify proteins with functional 
roles in regulating transcription which takes place inside. 
326 and 491 proteins were identified to sit close to dCas9 at Sites A and B, 
respectively. In order to make the list more manageable, they are filtered by 
multiple criteria detailed as follows. Firstly, proteins that overlap with the controls 
are eliminated and those between or within Sites A and B samples are processed. 
Next, they are selected using parameters related to the mass spectrometry step as a 
form of quality control. Proteins with a unique peptide of one are selected and this 
gives confidence that the ‘correct’ protein is identified. The remaining list of 
proteins is sorted from high to low according to a cumulative score, based on the 
aggregation of scores given to each protein from the RIME database; the higher the 
score, the more abundant it was in the sample. Then, to identify proteins that may 
regulate the expression of BCL11A, I select proteins that were expressed in the 
nucleus to proceed to the next criteria. These selected proteins are compared against 
an established database called Crapome, allowing me to remove common protein 
contaminants from proteomic studies. They are further compared against the cancer 
database, cBioPortal, in terms of their mRNA expressions against the PAM50 and 
correlation to BCL11A. PAM50 is an assay for classifying intrinsic breast cancer 
subtypes by quantifying the co-expression of 50 genes [27]. Lastly, only proteins 
with known roles in breast cancer are selected for further studies. These are DEK, 
SSRP1, and PSIP1.  
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To evaluate if these three factors are meaningful pull-downs, I first validate the 
cBioPortal data in which they are found to be upregulated in Basal-like breast 
cancer; 80% of this subtype is equivalent to TNBC. Proteins are collected from a 
panel of TNBC and Luminal cell lines and western blots are performed. Results 
reported in Figure 4.4 agree with the cBioportal database. However, their 
expression in Luminal as well as TNBC cell lines suggest that these proteins have 
general roles. Other than their subtype expressions, the binding of DEK, SSRP1 
and PSIP1 at the target sites and regions nearby are also validated in MDA-MB-
231 and HCC1569 TNBC cell lines. Similar to the ChIP-qPCR experiment 
described in Chapter 3, specific antibodies against factors are used to pull-down the 
DNA-bound proteins and these DNA regions are in turn amplified by specific 
primers. Figures 4.5- 4.8 confirm protein binding at Sites A and B and nearby 
regions. These results also verify that this RIME proteomics technique is applicable 
to the identification of unknown proteins. 
In a database called STRING, DEK is said to interact with SSRP1 and PSIP. I 
attempt to validate this in MDA-MB-231 cells by Co-Immunoprecipitation 
experiments using DEK as the central protein and for pulling down the other two 
factors. However, this proves to be challenging as the molecular weight of DEK is 
very close to the heavy chain of the Protein-G beads used. To resolve this, I switch 
to using Protein-A, which has a smaller molecular weight than DEK, as resin. 
Another merit of using Protein-A comes from its higher sensitivity for human 
Rabbit antibodies. From the Co-IP, I find that SSRP1 and PSIP1 are absent in the 
pulled-down samples. One possible explanation for this is that the MDA-MB-231 
wild type cells had little SSRP1 and PSIP1 expression and hence the majority of 
binding sites on the DEK antibodies is not occupied. To remedy this, Co-IP is 
performed in HCC1569 wild type cells which has been shown previously to have 
high expression of the three factors. Regrettably, I was unable to finish 
optimisations due to time constraints and was therefore unable to conclude if these 
three factors form a complex as suggested by the STRING database.  
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6.1.4 Implications of RIME pull-down 
Chapter 5 discussed the functional effects of DEK, SSRP1, and PSIP1, as well as 
their impacts on BCL11A’s expression in TNBC. These factors have known roles 
in cells and breast cancer, as reviewed in Table 4.11. I will briefly summarise and 
discuss their implications on my results here.  
DEK has been identified to organise chromatin which helps regulate transcription, 
for mRNA splicing, and for DNA replication and repair. In terms of expression, 
DEK protein is dependent on tRNA post-transcriptional modifying enzymes which 
in turn promote IRES-dependent translation for proteins such as LEF1 [152]. This 
study by Delaunay et al showed that such protein translation stimulates breast 
cancer invasion and metastasis. DEK has also been shown to maintain stemness 
[138] [139] and promotes mammosphere formation [138].  
SSRP1 is known to be a subunit of the FACT complex which regulates transcription 
[131] . It also aids transcription by dissociating histone proteins from active sites 
[131]  and acts as a transcriptional co-activator [132]. In terms of its roles in breast 
cancer, SSRP1 has been shown to be involved in cell proliferation, transformation 
, and maintaining stemness [142] [143].  
PSIP1 promotes transcription by acting as a transcriptional co-activator [135]. 
Moreover, it regulates the expression of cell cycle genes and is involved in tumour 
migration and invasion in breast cancer [144].  
Their roles in this project are investigated by the RNA interference technique, 
which uses shRNA (exogenous RNA) to target endogenous mRNA transcripts in 
order to achieve degradation and consequently a reduction in protein expression. 
This technique has the advantage of shRNA being constitutively expressed in the 
cells. In the single shRNA knock-down experiments, Figures 5.2- 5.4 show 
successful reduction of DEK, SSRP1 and PSIP1 expressions. However, these are 
not reflected in the protein levels of SSRP1 and PSIP1 p75 subunits. To understand 
the roles of these factors in this project better, I start by investigating their impacts 
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on the expression of BCL11A. Among them, knocking-down PSIP1 had no effect 
on BCL11A’s RNA expression but results in a partial reduction in its protein 
expression. These results suggest that PSIP1 was perhaps participating in regulating 
the translation of BCL11A. I then move on to investigate these factors’ functional 
roles using cell proliferation and colony formation assays. Knocking-down these 
factors individually did not have any effect on assays but this is not enough to 
completely rule out the possibility of them regulating the expression of BCL11A or 
their having functional effects by working with each other.  
To address this hypothesis, I continue the investigation by co-transfecting shRNA 
against two transcripts at the same time. Same as the results using single shRNA, 
the three factors are successfully knocked-down in both RNA and protein levels. 
Among these samples, the expression of BCL11A was also found to be reduced at 
both RNA and protein levels. However, only cells co-transfected with shRNAs 
against SSRP1 and PSIP1 did not affect PPP2R2D’s expression. PPP2R2D is a 
gene used as a control during RNA quantification and an example of housekeeping 
genes. These genes have functions that are important for cell survival and they are 
stably expressed in all biological systems [155]. For example, PPP2R2D is 
important for regulating a cell cycle check-point in mitosis [154]. Therefore, a 
reduction in this gene suggests that these proteins take part in regulating gene 
expressions on a global scale and this is also observed in cells transfected with DEK 
shRNA in Figure 5.7. On the other hand, no effect on the expression of PPP2R2D 
by knocking-down SSRP1 and PSIP1 suggests that these two proteins have 
potential roles in regulating the expression of BCL11A.  
Interpreting results from Chapter 5 in the context of existing literature leads to my 
proposal of how SSRP1 and PSIP1 may regulate BCL11A’s expression. Firstly, the 
fact that knocking-down PSIP1 alone has impact on BCL11A’s protein but not RNA 
expression suggests that PSIP1 has a role in regulating BCL11A’s translation. 
Secondly, PSIP1 is also thought to downregulate global gene expression. This is 
deduced from differences between the single knock-down of PSIP1 and double 
knock-down of PSIP1 and SSRP1. To quickly recap from Section 5.2.5.1, in both 
cases, SSRP1 is absent and an effect on global gene expression shown by the 
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reduction in PPP2R2D expression is observed when PSIP1 is present. Thirdly, 
SSRP1 and PSIP1 are thought to regulate BCL11A’s expression together. This 
interpretation is based on results showing no effects on the expression of BCL11A 
at the RNA level when knocking-down PSIP1 or SSRP1 alone; contrast this to the 
double knock-down of both at the same time which results in a significant reduction 
in BCL11A’s expression. These suggest that SSRP1 and PSIP1 may take part in 
regulating BCL11A’s expression and that they may act as transcriptional co-
activators. Furthermore, if PSIP1 does downregulate global gene expressions as 
suggested earlier, then there is the possibility that SSRP1 has also been 
downregulated. I therefore propose that SSRP1 may regulate BCL11A’s expression 
as a transcriptional co-activator while recruiting different transcription factors to 
those recruited by PSIP1.  
6.2 Future directions 
In this study, I have demonstrated that DEK, SSRP1 and PSIP1 are potential 
regulators of BCL11A using CRISPR-Cas9 and RIME techniques. However, there 
are several challenges that have to be addressed in the future. Improvements can 
also be made to the experiments to further extend our understanding on how these 
factors regulate the expression of BCL11A and their other roles in TNBC. 
Firstly, as discussed, I have adapted the CRISPR-Cas9 system to study transcription 
at transcription active sites of BCL11A. The use of dCas9 has allowed me to avoid 
DNA double-strand breaks and use this protein as a tag for the RIME experiment 
that follows. Since the start of this project, a better version has been identified – 
APEX-Cas9. Peroxidase APEX2 is fused with dCas9 in this system and its major 
benefit is the quick proximal labelling of protein interactions [158], compared to 
the 24 hours or more wait using the Tet-On system in our current experimental 
design. Another advantage of this proximal protein labelling is that APEX2 will 
biotinylate proteins in close proximity, thus pulling down only those biotinylated 
by APEX2 and minimise potential noise signals during protein identification in 
comparison to crosslinking by formaldehyde. This can lead to further elimination 
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of non-specific proteins that may sit in close proximity but does not participate in 
regulating BCL11A’s expression. A third benefit of this APEX-Cas9 system will be 
the delivery of one plasmid that co-expresses both APEX-Cas9 and the gRNA. In 
comparison to our current system, combining the components of the CRISPR-Cas9 
and this APEX system will allow us to speed up the process when establishing 
stable cell lines and mitigate challenges encountered in this project. 
Secondly, I have demonstrated that RIME can be applied to identify previously 
unknown proteins: DEK, SSRP1, and PSIP1. To establish if these proteins 
specifically regulate BCL11A’s expression in the breast cancer context, this 
technique with the CRISPR-Cas9 system should be applied to other cell lines 
including normal cells, various TNBC and Luminal cell lines. Analysing these 
RIME datasets might even broaden our view on BCL11A’s regulation in TNBC by 
identifying more putative factors. For instance, the identification of BCL11A as 
oncogene in Lung Squamous Carcinoma [73] makes it interesting to investigate 
whether DEK, SSRP1, and PSIP1 also participate in regulating BCL11A’s 
expression in that context. This will further contribute to our understanding of the 
regulation of BCL11A, regardless of whether it is specific or context dependent. 
Although the identification of these three factors shed light on the regulation of 
BCL11A, the pathway and mechanism are currently unknown. These should be the 
focus in the future using techniques such as RNA-sequencing to detect changes in 
gene expressions and mass spectrometry to compare protein expressions in the 
various conditions mentioned.  
Thirdly, I validated the expressions of DEK, SSRP1, and PSIP1 in various Luminal 
and TNBC cell lines. Aside from these cell lines, expressions of DEK, SSRP1, and 
PSIP1 should also be investigated in other breast cancer cell lines and PDXs. 
Moreover, their impacts on BCL11A’s expression have been determined and 
functional studies attempted. Again, these impacts should be investigated in other 
breast cancer cell lines, PDXs, and organoids. Additionally, more functional studies 
have to be done to conclude if DEK, SSRP1, and PSIP1 have any effects 
functionally. It would also be interesting to see if these factors bind at other genes 
by performing ChIP-sequencing. This procedure can potentially help us to 
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understand whether these factors bind at the same sites or act through other 
mechanisms such as recruiting other DNA regions, e.g. enhancers, to the promoter 
region of BCL11A and form DNA looping; or to identify potential downstream 
genes regulated by these factors or by our oncogene.  
The impact of BCL11A’s expression was investigated using shRNA knock-down. 
One criticism on the experimental design could be about the selection marker used 
in the combination shRNA knock-down experiments. To have confidence that the 
established cell line consists of plasmids that target different factors, several 
selection markers such as resistance genes for different antibiotics and different 
fluorescence markers should be used. Furthermore, the results from shRNA knock-
down in this project should be validated in other breast cancer cell lines, PDXs, and 
organoids; and investigated further in mouse models. Another challenge I have 
encountered after establishing stable cell lines to co-express two shRNAs was the 
reduction in growth rate. This could be tackled in the future using inducible shRNA 
plasmids and extending the project to further understand the effects of these three 
proteins by knocking them all down at the same time.  
Therapeutic potential implied by my current results can be further investigated 
using existing drugs, such as CBL0137 which affects SSRP1 functions [159] [160] 
[161] [162] [163] [164] and is currently administered as a therapy for hematological 
malignancies [165] and undergoing clinical trial for treating small cell lung cancer 
[163]. CBL0137 is a Curaxcin-based drug that acts by changing the topology of 
DNA through intercalation [160]. The consequence of this is that the FACT 
complex, which consists of SSRP1 and SPT16H subunits, becomes unable to bind 
to DNA and transcribe genes such as the Nuclear Factor kappa-light-chain-
enhancer of activated B cells (NF-κB) [160] [166]. The inhibition of the expression 
of NF-κB induces cell apoptosis [166]. At the same time, CBL0137 also promotes 
the formation of a complex with the FACT complex and Caesin kinase 2 (CK2), 
and phosphorylates the Serine at position 392 of p53 which then activates p53 
[148]. This simultaneous mechanism of CBL0137 results in a reduction in tumour 
growth and induces cell apoptosis.  
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Lastly, I have attempted to establish if these three proteins form a protein complex. 
However, this has proven to be technical challenging and I was unable to finish 
optimisations due to time constraints. The Co-IP experiment could be further 
optimised and the investigation could be extended to multiple breast cancer cell 
lines and tumour samples. 
6.3 Conclusion 
To conclude, I established a novel system to study transcriptional regulation of 
BCL11A in TNBC using the CRISPR-Cas9 system and identify three factors as 
potential regulators using RIME proteomics. Adaptation of the CRISPR-Cas9 
system in this project involves using dCas9 to not generate DNA double-strand 
breaks but as a tag for pulling down itself with proteins in close proximity at our 
sites of interests. Analysis of these proteins with the RIME proteomics dataset using 
multiple parameters and criteria leads to the identification of DEK, SSRP1, and 
PSIP1. From there, their effects on the expression of BCL11A were investigated 
using shRNA knock-down. Combining results from different knock-down 
experiments, I propose that SSRP1 and PSIP1 play a bigger role in regulating 
BCL11A’s expression through different mechanisms. These results imply that DEK, 
SSRP1, and PSIP1 could be potential drug targets when developing therapeutic 
targets against BCL11A specifically for TNBC. This implication is particularly 
important when seen as a potential answer to the clinical challenges of targeting 
BCL11A due to its general importance in celluar functions and development outside 
of the TNBC context, as previously mentioned in the original aims and rationales 
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List of proteins after the elimination of common proteins between 
IgG and the triplicates of Site A samples 
UniProt Gene ID UniProt Gene ID 
P11388 TOP2A P06733 ENO1 
O00567 NOP56 P61313 RPL15 
Q9UKM9 RALY P46781 RPS9 
Q8IY81 FTSJ3 P67936 TPM4 
O60832 DKC1 P27348 YWHAQ 
O43290 SART1 P50914 RPL14 
Q9BY78 RNF26 P46776 RPL27A 
Q9Y3Y3 SH2B1 P0DMV9 HSPA1B 
P46013 MKI67 P01859 IGHG2 
Q9Y2X4 SH2D3A Q14137 BOP1 
P82980 RBP5 P46087 NOP2 
Q08945 SSRP1 O75531 BANF1 
Q9Y5S1 TRPV2 Q8TDN6 BRIX1 
Q05519 SRSF11 P98179 RBM3 
Q9Y5B9 RBM8A P09211 GSTP1 
Q13186 SPTAN1 P12270 TPR 
P27694 RPA1 P61513 RPL37A 
P26583 HMGB2 Q9Y2L1 DIS3 
P35659 DEK P62306 SNRPF 
P09874 PARP1 Q2TAY7 SMU1 
Q92945 KHSRP Q08J23 NSUN2 
P52597 HNRNPF O00541 PES1 
P11387 TOP1 Q9BY42 RTFDC1 
Q99729 HNRNPAB Q13148 TARDBP 
O43707 ACTN4 P13984 GTF2F2 
P62750 RPL23A O75475 PSIP1 
O43143 DHX15 O95232 LUC7L3 
P29692 EEF1D P68371 TUBB4B 
Q9UQ35 SRRM2 P07900 HSP90AA1 
P18621 RPL17 Q7Z794 KRT77 
Appendix table A1: List of the proteins after the elimination of common 
proteins between IgG and the triplicates at Site A.  
Table shows the proteins remained after the elimination of common proteins 
between IgG control and the triplicates of Site A samples, presented in UniProt and 
Gene ID. 
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List of proteins after the elimination of common proteins between IgG 
and triplicates at Site B 
UniProt Gene ID UniProt Gene ID UniProt Gene ID 
Q09666 AHNAK P35637 FUS P83731 RPL24 
Q86V81 ALYREF O75367 H2AFY P61353 RPL27 
O00148 DDX39A P19105 MYL12A P55884 EIF3B 
P68032 ACTC1 Q02218 OGDH P05388 RPLP0 
Q9NZM1 MVOF A0M8Q6 IGLC7 P62750 RPL23A 
P12956 XRCC6 P40227 CCT6A O95486 SEC24A 
P09651 HNRNPA1 P04083 ANXA1 P21399 ACO1 
P55795 HNRNPH2 P49368 CCT3 Q9NQ29 LUC7L2 
P23396 RPS3 P38159 RBMX P56537 EIF6 
P17844 DDX5 P04075 ALDOA P78371 CCT2 
P11021 HSPA5 P06753 TPM3 Q13242 SRSF9 
Q03426 MVK P62241 RPS8 P30050 RPL12 
P34932 HSPA4 P17987 TCP1 O15371 EIF3D 
O94979 SEC31A O00299 CLIC1 Q01130 SRSF2 
P13647 KRT5 P55209 NAP1L1 Q15785 TOMM34 
Q14103 HNRNPD Q99873 PRMT1 P04792 HSPB1 
P62333 PSMC6 Q86V48 LUZP1 P21589 NT5E 
Q96S55 WRNIP1 P55072 VCP Q13547 HDAC1 
P62937 PPIA P14625 HSP90B1 P62249 RPS16 
Q9UHX1 PUF60 P15880 RPS2 P61326 MAGOH 
P42167 TMPO Q9H0S4 DDX47 P27797 CALR 
P18124 RPL7 P36957 DLST P48643 CCT5 
O60506 SYNCRIP O75643 SNRNP200 O75400 PRPF40A 
P63241 EIF5A Q15393 SF3B3 Q15365 PCBP1 
P62424 RPL7A P42704 LRPPRC P07195 LDHB 
P60660 MYL6 P49454 CENPF P62081 RPS7 
Q8ND24 RNF214 P53396 ACLY P27635 RPL10 
O43166 SIPA1L1 P17980 PSMC3 P26358 DNMT1 
Q9Y230 RYVBL2 P62906 RPL10A P23526 AHCY 
P13639 EEF2 P38646 HSPA9 P04844 RPN2 
Q96J42 TXNDC15 P12268 IMPDH2 O14980 XPO1 
P50990 CCT8 Q9Y265 RUVBL1 P63173 RPL38 
P00558 PGK1 P24534 EEF1B2 P51114 FXR1 
P63104 YWHAZ Q2TAZ0 ATG2A Q53F19 NCBP3 
Q99848 EBNA1BP2 P36578 RPL4 P28070 PSMB4 
P52292 KPNA2 Q13200 PSMD2 O75821 EIF3G 
P48444 ARCN1 P21291 CSRP1 P43686 PSMC4 
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UniProt Gene ID UniProt Gene ID UniProt Gene ID 
P46778 RPL21 P28799 GRN Q96AE4 FUBP1 
Q01518 CAP1 Q9UK45 LSM7 P33992 MCM5 
P31949 S100A11 Q9Y3I0 RTCB Q9NWB6 ARGLU1 
Q96FW1 OTUB1 P25398 RPS12 Q6P1J9 CDC73 
P62266 RPS23 Q969E4 TCEAL3 P25685 DNAJB1 
P30085 CMPK1 O76021 RSL1D1 Q96I24 FUBP3 
Q16555 DPYSL2 Q8NBT2 SPC24 P40121 CAPG 
Q8WXA9 SREK1 O14818 PSMA7 P20290 BTF3 
P06576 ATP5F1B Q9UGR2 ZC3H7B P25787 PSMA2 
P60900 PSMA6 P15531 NME1 Q9NTK5 OLA1 
Q7L014 DDX46 Q96QD9 FYTTD1 Q9Y266 NUDC 
P49756 RBM25 Q9HB71 CACYBP Q8WXF0 SRSF12 
Q8WXF1 PSPC1 Q9BZZ5 API5 P46060 RANGAP1 
P31689 DNAJA1 Q9BVP2 GNL3 Q9UNX4 WDR3 
P28066 PSMA5 Q96PK6 RBM14 P62318 SNRPD3 
O94776 MTA2 O43818 RRP9 P14678 SNPRB 
P05455 SSB O43172 PRPF4 O43670 ZNF207 
Q9H307 PNN P07305 H1F0 P46783 RPS10 
P55769 SNU13 P43487 RANBP1 Q09028 RBBP4 
Q9Y3U8 RPL36 Q99459 CDC5L P39656 DDOST 
P62269 RPS18 Q9H0A0 NAT10 Q8N684 CPSF7 
Q13347 EIF3I Q6PJT7 ZC3H14 Q99829 CPNE1 
P00846 MT-ATP6 Q15427 SF3B4 Q9Y6A5 TACC3 
P18077 RPL35A P43490 NAMPT Q8IYB3 SRRM1 
Q9NVC6 MED17 Q15942 ZYX Q96AG4 LRRC59 
O76003 GLRX3 P35268 RPL22 P61026 RAB10 
Q14683 SMC1A P12081 HARS P10599 TXN 
P42677 RPS27 
Appendix table A2: List of the proteins after the elimination of common 
proteins between IgG and triplicates of Site B. 
Table shows proteins remained for further analysis after the elimination of common 
proteins between IgG and the triplicates of Site B samples, presented in UniProt 
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List of proteins after the elimination of common proteins between IgG 
and the triplicates of Sites A and B 
UniProt Gene ID UniProt Gene ID UniProt Gene ID 
P21333 FLNA Q07666 KHDRBS1 Q03252 LMNB2 
O75369 FLNB O75083 WDR1 Q9BTT0 ANP32E 
Q14204 DYNC1H1 P22087 FBL P35244 RPA3 
Q13838 DDX39B Q9Y5B9 SUPT16H P62316 SNRPD2 
P38919 EIF4A3 Q07955 SRSF1 Q9NQW6 ANLN 
O75533 SF3B1 Q08945 SSRP1 P31942 HNRNPH3 
P13010 XRCC5 P13489 RNH1 Q86U42 PABPN1 
O15027 SEC16A P0C0L4 C4A Q9UKV3 ACIN1 
P11940 PABPC1 P35659 DEK P62158 CALM 
Q9BY77 POLDIP3 Q13151 HNRNPA0 P0DN76 U2AF1L5 
Q9Y3Y2 CHTOP P26583 HMGB2 P62273 RPS29 
P08865 RPSA Q13247 SRSF6 P61254 RPL26 
P46013 MKI67 P63220 RPS21 Q14498 RBM39 
Q13263 TRIM28 Q16629 SRSF7 Q9Y5S9 RBM8A 
Q15233 NONO Q9Y3B4 SF3B6 Q05519 SRSF11 
P06899 HIST1H2BJ Q01105 SET Q15717 ELAVL1 
Q92841 DDX17 Q9Y2W1 THRAP3 Q14847 LASP1 
P82979 SARNP P62847 RPS24 Q13185 CBX3 
Q12906 ILF3 P84103 SRSF3 P0C0S5 H2AFZ 
P09429 HMGB1 Q9BZE4 GTPBP4 Q9Y383 LUC7L2 
Q9Y2X3 NOP58 P27694 RPA1 O14979 HNRNPDL 
P43243 MATR3 Q15287 RNPS1 P53999 SUB1 
P67809 YBX1 P62314 SNRPD1 Q12905 ILF2 
P11388 TOP2A P17096 HMGA1 P20700 LMNB1 
Appendix table A3: List of the proteins remained after the elimination of 
common proteins between the IgG control and the triplicates of Sites A and B. 
Table shows the proteins remained after the elimination of common proteins 
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Proteins with nuclear expressions at Site A 
































Appendix table A4: Proteins pulled-down from Site A with nuclear 
expressions. 
Table shows list of proteins with nuclear expressions pulled-down in RIME from 
Site A, presented in UniProt and Gene ID. 
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Proteins with nuclear expressions at Site B 
UniProt Gene ID UniProt Gene ID UniProt Gene ID 
Q09666 AHNAK Q9H307 PNN P46060 RANGAP1 
Q9NZM1 MYOF P55769 SNU13 Q9UNX4 WDR3 
P62333 PSMC6 Q9Y3U8 RPL36 Q8N684 CPSF7 
Q96S55 WRNIP1 Q9NVC6 MED17 Q99829 CPNE1 
Q8ND24 RNF214 O43670 ZNF207 Q96AE4 FUBP1 
O75367 H2AFY Q9UK45 LSM7 P33992 MCM5 
P04083 ANXA1 O76021 RSL1D1 Q9NWB6 ARGLU1 
O00299 CLIC1 Q8NBT2 SPC24 Q6P1J9 CDC73 
Q86V48 LUZP1 O14818 PSMA7 P25685 DNAJB1 
Q9H0S4 DDX47 Q9UGR2 ZC3H7B Q96I24 FUBP3 
P49454 CENPF P15531 NME1 Q96AG4 LRRC59 
P12268 IMPDH2 Q96QD9 FYTTD1 Q8IYB3 SRRM1 
Q2TAZ0 ATG2A Q9HB71 CACYBP P40121 CAPG 
P56537 EIF6 Q9BZZ5 API5 P20290 BTF3 
Q13242 SRSF9 Q9BVP2 GNL3 P25787 PSMA2 
P04792 HSPB1 Q96PK6 RBM14 Q9NTK5 OLA1 
P61326 MAGOH O43818 RRP9 Q9Y266 NUDC 
O75400 PRPF40A O43172 PRPF4 Q8WXF0 SRSF12 
P26358 DNMT1 P07305 H1F0 P31949 S100A11 
O14980 XOP1 P43487 RANBP1 P30085 CMPK1 
Q53F19 NCBP3 Q99459 CDC5L Q8WXA9 SREK1 
P28070 PSMB4 Q9H0A0 NAT10 P60900 PSMA6 
Q99848 EBNA1BP2 Q6PJT7 ZC3H14 P49756 RBM25 
P21291 CSRP1 Q15427 SF3B4 Q8WXF1 PSPC1 
P43686 PSMC4 P43490 NAMPT P28066 PSMA5 
Q14683 SMC1A Q15942 ZYX O94776 MTA2 
Appendix table A5: Proteins with nuclear expressions pulled-down in RIME 
at Site B. 
Table shows proteins with nuclear expressions from RIME analysis at Site B, 
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Common proteins with nuclear expressions from Sites A and B 

























Appendix table A6: Common proteins between Sites A and B with nuclear 
expressions. 
Table shows common proteins pulled-down from Sites A and B in RIME with 
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Appendix table A7: Proteins with less than 100 studies from the Crapome 
database at Site A. 
Common proteins from the triplicates of Site A in RIME analysis with less than 


















Proteins from Crapome database (>100 studies) at Site A 
UniProt Gene ID UniProt Gene ID 
O00567 NOP56 P09211 GSTP1 
Q9UKM9 RALY P12270 TPR 
Q8IY81 FTSJ3 P61513 RPL37A 
O60832 DKC1 Q9Y2L1 DIS3 
O43290 SART1 P62306 SNRPF 
Q9BY78 Rnf26 Q2TAY7 SMU1 
Q9Y3Y3 SH2B1 Q08J23 NSUN2 
P46013 MKI67 O00541 PES1 
Q9Y2X4 SH2D3A Q9BY42 RTFDC1 
O75475 PSIP1 Q13148 TARDBP 
P82980 RBP5 P13984 GTF2F2 
Q08946 EZR P27694 RPA1 
Q9Y5S1 TRPV2 P26583 HMGB2 
Q05519 SRSF11 Q14137 BOP1 
Q9Y5B1 PPA1 P46087 NOP2 
Q13186 SPTAN1 O75531 BANF1 
P11388 TOP2A Q8TDN6 BRIX1 
P98179 RBM3 
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Appendix table A8: Proteins after the analysis with Crapome study at Site B.  
Table showing common proteins from the triplicates at Site B in RIME with less 
than 100 studies from the Crapome database, presented in Uniprot and Gene ID. 
Proteins from Crapome database (>100 studies) at Site B 
UniProt Gene ID UniProt Gene ID UniProt Gene ID 
Q09666 AHNAK Q9NVC6 MED17 O43172 PRPF4 
Q9NZM1 MYOF O43670 ZNF207 P07305 H1F0 
P62333 PSMC6 Q9UK45 LSM7 P43487 RANBP1 
Q96S55 WRNIP1 O94979 SEC31A Q99459 CDC5L 
Q8ND24 RNF214 O43166 SIPA1L1 Q9H0A0 NAT10 
O75367 H2AFY P00558 PGK1 Q6PJT7 ZC3H14 
P04083 ANXA1 Q02218 PGDH Q15427 SF3B4 
O00299 CLIC1 P36957 DLST P43490 NAMPT 
Q86V48 LUZP1 O95486 SEC24A Q15942 ZYX 
Q9H0S4 DDX47 P21399 ACO1 Q96AG4 LRRC59 
P49454 CENPF O15371 EIF3D Q8IYB3 SRRM1 
P12268 IMPDH2 Q15785 TOMM34 P40121 CAPG 
Q2TAZ0 ATG2A P21589 NT5E P20290 BTF3 
P56537 EIF6 P23526 AHCY P25787 PSMA2 
Q13242 SRSF9 P04844 RPN2 Q9NTK5 OLA1 
P04792 HSPB1 P51114 FXR1 Q9Y266 NUDC 
P61326 MAGOH P48444 ARCN1 Q8WXF0 SRSF12 
O75400 PRPF40A P12081 HARS P46060 RANGAP1 
P26358 DNMT1 P61026 RAB10 Q9UNX4 WDR3 
O14980 XPO1 Q01518 CAP1 Q8N684 CPSF7 
Q53F19 NCBP3 Q96FW1 OTUB1 Q99829 CPNE1 
P28070 PSMB4 Q16555 DPYSL2 Q96AE4 FUBP1 
Q99848 EBNA1P2 P00846 MT-ATP6 P33992 MCM5 
P21291 CSRP1 O76003 GLRX3 Q9NWB6 ARGLU1 
P43686 PSMC4 Q9Y6A5 TACC3 Q6P1J9 CDC73 
Q14683 SMC1A P39656 DDOST P25685 DNAJB1 
P31949 S100A11 P28799 GRN Q96I24 FUBP3 
P30085 CMPK1 O76021 RSL1D1 Q9H307 PNN 
Q8WXA9 SREK1 Q8NBT2 SPC24 P55769 SNU13 
P60900 PSMA6 O14818 PSMA7 Q9Y3U8 RPL36 
P49756 RBM25 Q9UGR2 ZC3H7B Q9BZZ5 API5 
Q8WXF1 PSPC1 P15531 NME1 Q9BVP2 GNL3 
P28066 PSMA5 Q96QD9 FYTTD1 Q96PK6 RBM14 
O94776 MTA2 Q9HB71 CACYBP O43818 RRP9 
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Common proteins from Crapome database (>100 studies) between 
Sites A and B 






























Appendix table A9: Common proteins from the Crapome database with less 
than 100 studies between Sites A and B. 
Table shows common proteins between Sites A and B with less than 100 studies 
from the Crapome database, presented in Uniprot and Gene ID. 
 
 
